

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number
WO 01/00844 A2

(51) International Patent Classification ⁷ :	C12N 15/31, 15/55, 1/21, 9/18, C07K 14/34, C12P 13/08, C12Q 1/68	199 42 088.2 199 42 095.5 199 42 123.4 199 42 125.0	3 September 1999 (03.09.1999) 3 September 1999 (03.09.1999) 3 September 1999 (03.09.1999) 3 September 1999 (03.09.1999)	DE DE DE DE
(21) International Application Number:	PCT/IB00/00943			
(22) International Filing Date:	23 June 2000 (23.06.2000)			
(25) Filing Language:	English			
(26) Publication Language:	English			
(30) Priority Data:				
60/141,031	25 June 1999 (25.06.1999)	US		
199 31 562.0	8 July 1999 (08.07.1999)	DE		
199 31 634.1	8 July 1999 (08.07.1999)	DE		
199 31 412.8	8 July 1999 (08.07.1999)	DE		
199 31 413.6	8 July 1999 (08.07.1999)	DE		
199 31 419.5	8 July 1999 (08.07.1999)	DE		
199 31 420.9	8 July 1999 (08.07.1999)	DE		
199 31 424.1	8 July 1999 (08.07.1999)	DE		
199 31 428.4	8 July 1999 (08.07.1999)	DE		
199 31 431.4	8 July 1999 (08.07.1999)	DE		
199 31 433.0	8 July 1999 (08.07.1999)	DE		
199 31 434.9	8 July 1999 (08.07.1999)	DE		
199 31 510.8	8 July 1999 (08.07.1999)	DE		
60/143,208	9 July 1999 (09.07.1999)	US		
199 32 180.9	9 July 1999 (09.07.1999)	DE		
199 32 227.9	9 July 1999 (09.07.1999)	DE		
199 32 230.9	9 July 1999 (09.07.1999)	DE		
199 33 005.0	14 July 1999 (14.07.1999)	DE		
199 32 924.9	14 July 1999 (14.07.1999)	DE		
199 32 973.7	14 July 1999 (14.07.1999)	DE		
199 40 765.7	27 August 1999 (27.08.1999)	DE		
60/151,572	31 August 1999 (31.08.1999)	US		
199 42 076.9	3 September 1999 (03.09.1999)	DE		
199 42 079.3	3 September 1999 (03.09.1999)	DE		
199 42 086.6	3 September 1999 (03.09.1999)	DE		
199 42 087.4	3 September 1999 (03.09.1999)	DE		

(71) Applicant: BASF AKTIENGESELLSCHAFT
[DE/DE]; D-67056 Ludwigshafen (DE).

(72) Inventors: POMPEJUS, Markus; Wenjenstrasse 21,
D-67251 Freinsheim (DE). KRÖGER, Burkhard; Im
Waldhof 1, D-67117 Limburgerhof (DE). SCHRÖDER,
Hartwig; Goethestrasse 5, D-69226 Nussloch (DE).
ZELDER, Oskar; Rossmarktstrasse 27, D-67346 Speyer
(DE). HABERHAUER, Gregor; Moselstrasse 42,
D-67117 Limburgerhof (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 01/00844 A2

(54) Title: CORYNEBACTERIUM GLUTAMICUM GENES ENCODING PROTEINS INVOLVED IN CARBON METABOLISM
AND ENERGY PRODUCTION

(57) Abstract: Isolated nucleic acid molecules, designated SMP nucleic acid molecules, which encode novel SMP proteins from *Corynebacterium glutamicum* are described. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SMP nucleic acid molecules, and host cells into which the expression vectors have been introduced. The invention still further provides isolated SMP proteins, mutated SMP proteins, fusion proteins, antigenic peptides and methods for the improvement of production of a desired compound from *C. glutamicum* based on genetic engineering of SMP genes in this organism.

**CORYNEBACTERIUM GLUTAMICUM GENES ENCODING PROTEINS
INVOLVED IN CARBON METABOLISM AND ENERGY PRODUCTION**

Related Applications

5 This application claims priority to prior U.S. Provisional Patent Application Serial No. 60/141031, filed June 25, 1999, U.S. Provisional Patent Application Serial No. 60/143208, filed July 9, 1999, and U.S. Provisional Patent Application Serial No. 60/151572, filed August 31, 1999. This application also claims priority to prior German Patent Application No. 19931412.8, filed July 8, 1999, German Patent Application No. 19931413.6, filed July 8, 1999, German Patent Application No. 19931419.5, filed July 8, 1999, German Patent Application No. 19931420.9, filed July 8, 1999, German Patent Application No. 19931424.1, filed July 8, 1999, German Patent Application No. 19931428.4, filed July 8, 1999, German Patent Application No. 19931431.4, filed July 8, 1999, German Patent Application No. 19931433.0, filed July 8, 1999, German Patent Application No. 19931434.9, filed July 8, 1999, German Patent Application No. 19931562.0, filed July 8, 1999, German Patent Application No. 19931634.1, filed July 8, 1999, German Patent Application No. 19932180.9, filed July 9, 1999, German Patent Application No. 19932227.9, filed July 9, 1999, German Patent Application No. 19932924.9, filed July 14, 1999, German Patent Application No. 19932973.7, filed July 14, 1999, German Patent Application No. 19940765.7, filed 19933005.0, filed July 14, 1999, German Patent Application No. 19942076.9, filed September 3, 1999, August 27, 1999, German Patent Application No. 19942079.3, filed September 3, 1999, German Patent Application No. 19942086.6, filed September 3, 1999, German Patent Application No. 19942087.4, filed September 3, 1999, German Patent Application No. 19942088.2, filed September 3, 1999, German Patent Application No. 19942095.5, filed September 3, 1999, German Patent Application No. 19942123.4, filed September 3, 1999, and German Patent Application No. 19942125.0, filed September 3, 1999. The entire contents of all of the aforementioned application are hereby expressly incorporated herein by this reference.

Background of the Invention

Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries. These molecules, collectively termed 'fine chemicals', 5 include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic compounds, vitamins and cofactors, and enzymes. Their production is most conveniently performed through the large-scale culture of bacteria developed to produce and secrete large quantities of one or more desired molecules. One particularly useful 10 organism for this purpose is *Corynebacterium glutamicum*, a gram positive, nonpathogenic bacterium. Through strain selection, a number of mutant strains have been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-consuming and difficult process.

15

Summary of the Invention

The invention provides novel bacterial nucleic acid molecules which have a variety of uses. These uses include the identification of microorganisms which can be used to produce fine chemicals, the modulation of fine chemical production in *C. glutamicum* or related bacteria, the typing or identification of *C. glutamicum* or related bacteria, as reference points for mapping the *C. glutamicum* genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as sugar metabolism and oxidative phosphorylation (SMP) proteins.
20 *C. glutamicum* is a gram positive, aerobic bacterium which is commonly used in industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids. The SMP nucleic acid molecules of the invention, therefore, can be used to 25 identify microorganisms which can be used to produce fine chemicals, e.g., by modulation of the expression of the SMP nucleic acids of the invention, or modification of the sequence of the SMP nucleic acid molecules of the 30 invention, can be used to modulate the production of one or more fine chemicals from a

microorganism (e.g., to improve the yield or production of one or more fine chemicals from a *Corynebacterium* or *Brevibacterium* species).

The SMP nucleic acids of the invention may also be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof, or to identify the presence of *C. glutamicum* or a relative thereof in a mixed population of 5 microorganisms. The invention provides the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain 10 whether this organism is present. Although *Corynebacterium glutamicum* itself is nonpathogenic, it is related to species pathogenic in humans, such as *Corynebacterium diphtheriae* (the causative agent of diphtheria); the detection of such organisms is of significant clinical relevance.

The SMP nucleic acid molecules of the invention may also serve as reference 15 points for mapping of the *C. glutamicum* genome, or of genomes of related organisms. Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered *Corynebacterium* or *Brevibacterium* species.

The SMP proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, performing a function involved in the metabolism of carbon 20 compounds such as sugars or in the generation of energy molecules by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*. Given the availability of cloning vectors for use in *Corynebacterium glutamicum*, such as those disclosed in Sinskey *et al.*, U.S. Patent No. 4,649,119, and techniques for genetic manipulation of *C. glutamicum* and the related *Brevibacterium* species (e.g., *lactofermentum*) (Yoshihama 25 *et al.*, *J. Bacteriol.* 162: 591-597 (1985); Katsumata *et al.*, *J. Bacteriol.* 159: 306-311 (1984); and Santamaria *et al.*, *J. Gen. Microbiol.* 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this 30 organism to make it a better or more efficient producer of one or more fine chemicals. This improved production or efficiency of production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation.

There are a number of mechanisms by which the alteration of an SMP protein of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a *C. glutamicum* strain incorporating such an altered protein. The degradation of high-energy carbon molecules such as sugars, and the conversion of compounds such as NADH and FADH₂ to compounds containing high energy phosphate bonds via oxidative phosphorylation results in a number of compounds which themselves may be desirable fine chemicals, such as pyruvate, ATP, NADH, and a number of intermediate sugar compounds. Further, the energy molecules (such as ATP) and the reducing equivalents (such as NADH or NADPH) produced by these metabolic pathways are utilized in the cell to drive reactions which would otherwise be energetically unfavorable. Such unfavorable reactions include many biosynthetic pathways for fine chemicals. By improving the ability of the cell to utilize a particular sugar (e.g., by manipulating the genes encoding enzymes involved in the degradation and conversion of that sugar into energy for the cell), one may increase the amount of energy available to permit unfavorable, yet desired metabolic reactions (e.g., the biosynthesis of a desired fine chemical) to occur.

The mutagenesis of one or more SMP genes of the invention may also result in SMP proteins having altered activities which indirectly impact the production of one or more desired fine chemicals from *C. glutamicum*. For example, by increasing the efficiency of utilization of one or more sugars (such that the conversion of the sugar to useful energy molecules is improved), or by increasing the efficiency of conversion of reducing equivalents to useful energy molecules (e.g., by improving the efficiency of oxidative phosphorylation, or the activity of the ATP synthase), one can increase the amount of these high-energy compounds available to the cell to drive normally unfavorable metabolic processes. These processes include the construction of cell walls, transcription, translation, and the biosynthesis of compounds necessary for growth and division of the cells (e.g., nucleotides, amino acids, vitamins, lipids, etc.) (Lengeler *et al.* (1999) *Biology of Prokaryotes*, Thieme Verlag: Stuttgart, p. 88-109; 913-918; 875-899). By improving the growth and multiplication of these engineered cells, it is possible to increase both the viability of the cells in large-scale culture, and also to improve their rate of division, such that a relatively larger number of cells can survive in fermentor culture. The yield, production, or efficiency of production may be increased, at least

due to the presence of a greater number of viable cells, each producing the desired fine chemical. Also, many of the degradation products produced during sugar metabolism are utilized by the cell as precursors or intermediates in the production of other desirable products, such as fine chemicals. So, by increasing the ability of the cell to metabolize sugars, the number of these degradation products available to the cell for other processes should also be increased.

5 The invention provides novel nucleic acid molecules which encode proteins, referred to herein as SMP proteins, which are capable of, for example, performing a function involved in the metabolism of carbon compounds such as sugars and the 10 generation of energy molecules by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*. Nucleic acid molecules encoding an SMP protein are referred to herein as SMP nucleic acid molecules. In a preferred embodiment, the SMP protein participates in the conversion of carbon molecules and degradation products thereof to energy which is utilized by the cell for metabolic processes. Examples of 15 such proteins include those encoded by the genes set forth in Table 1.

Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding an SMP protein or biologically active portions thereof, as well as nucleic acid fragments 20 suitable as primers or hybridization probes for the detection or amplification of SMP-encoding nucleic acid (e.g., DNA or mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth as the odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....), or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the 25 isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth as an odd-numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....), or a portion thereof. In other preferred embodiments, the isolated 30 nucleic acid molecule encodes one of the amino acid sequences set forth as an even-numbered SEQ ID NO in the Sequence Listing (e.g., SEQ ID NO:2, SEQ ID NO:4, SEQ

ID NO:6, SEQ ID NO:8....). The preferred SMP proteins of the present invention also preferably possess at least one of the SMP activities described herein.

In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence having an even-numbered SEQ ID NO: in the Sequence Listing), e.g., 5 sufficiently homologous to an amino acid sequence of the invention such that the protein or portion thereof maintains an SMP activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to perform a function involved in the metabolism of carbon compounds such as sugars or the generation of 10 energy molecules (e.g., ATP) by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90% and most preferably at least about 95%, 96%, 97%, 15 98%, or 99% or more homologous to an amino acid sequence of the invention (e.g., an entire amino acid sequence selected those having an even-numbered SEQ ID NO in the Sequence Listing). In another preferred embodiment, the protein is a full length *C. glutamicum* protein which is substantially homologous to an entire amino acid sequence 20 of the invention (encoded by an open reading frame shown in the corresponding odd-numbered SEQ ID NOs in the Sequence Listing (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7....).

In another preferred embodiment, the isolated nucleic acid molecule is derived from *C. glutamicum* and encodes a protein (e.g., an SMP fusion protein) which includes 25 a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of one of the even-numbered SEQ ID NOs in the Sequence Listing) and is able to perform a function involved in the metabolism of carbon compounds such as sugars or the generation of energy molecules (e.g., ATP) by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*, or has one or more of the activities set forth in Table 1, and which also 30 includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.

In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of the invention (e.g., a sequence of an odd-numbered SEQ ID NO in the Sequence Listing) A. Preferably, the isolated nucleic acid 5 molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring *C. glutamicum* SMP protein, or a biologically active portion thereof.

Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which 10 such vectors have been introduced. In one embodiment, such a host cell is used to produce an SMP protein by culturing the host cell in a suitable medium. The SMP protein can be then isolated from the medium or the host cell.

Yet another aspect of the invention pertains to a genetically altered microorganism in which an SMP gene has been introduced or altered. In one 15 embodiment, the genome of the microorganism has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated SMP sequence as a transgene. In another embodiment, an endogenous SMP gene within the genome of the microorganism has been altered, e.g., functionally disrupted, by homologous recombination with an altered SMP gene. In another embodiment, an endogenous or 20 introduced SMP gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional SMP protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an SMP gene in a microorganism has been altered (e.g., by deletion, truncation, inversion, or point mutation) such that the expression of the SMP gene is 25 modulated. In a preferred embodiment, the microorganism belongs to the genus *Corynebacterium* or *Brevibacterium*, with *Corynebacterium glutamicum* being particularly preferred. In a preferred embodiment, the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred.

30 In another aspect, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the

sequences set forth in the Sequence Listing as SEQ ID NOs 1 through 782) in a subject, thereby detecting the presence or activity of *Corynebacterium diphtheriae* in the subject.

Still another aspect of the invention pertains to an isolated SMP protein or a portion, e.g., a biologically active portion, thereof. In a preferred embodiment, the isolated SMP protein or portion thereof is capable of performing a function involved in the metabolism of carbon compounds such as sugars or in the generation of energy molecules (e.g., ATP) by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*. In another preferred embodiment, the isolated SMP protein or portion thereof is sufficiently homologous to an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: in the Sequence Listing) such that the protein or portion thereof maintains the ability to perform a function involved in the metabolism of carbon compounds such as sugars or in the generation of energy molecules (e.g., ATP) by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*.

The invention also provides an isolated preparation of an SMP protein. In preferred embodiments, the SMP protein comprises an amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing). In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) (encoded by an open reading frame set forth in a corresponding odd-numbered SEQ ID NO: of the Sequence Listing). In yet another embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an entire amino acid sequence of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing). In other embodiments, the isolated SMP protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of the invention (e.g., a sequence of an even-numbered SEQ ID NO: of the Sequence Listing) and is able to perform a function involved in the metabolism of carbon compounds such as sugars or in the generation of energy molecules (e.g., ATP) by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*, or has one or more of the activities set forth in Table 1.

Alternatively, the isolated SMP protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 5 95%, 96%, 97%, 98%, or 99% or more homologous to a nucleotide sequence of one of the even-numbered SEQ ID NOS set forth in the Sequence Listing. It is also preferred that the preferred forms of SMP proteins also have one or more of the SMP bioactivities described herein.

The SMP polypeptide, or a biologically active portion thereof, can be operatively 10 linked to a non-SMP polypeptide to form a fusion protein. In preferred embodiments, this fusion protein has an activity which differs from that of the SMP protein alone. In other preferred embodiments, this fusion protein performs a function involved in the metabolism of carbon compounds such as sugars or in the generation of energy molecules (e.g., ATP) by processes such as oxidative phosphorylation in 15 *Corynebacterium glutamicum*. In particularly preferred embodiments, integration of this fusion protein into a host cell modulates production of a desired compound from the cell.

In another aspect, the invention provides methods for screening molecules which 20 modulate the activity of an SMP protein, either by interacting with the protein itself or a substrate or binding partner of the SMP protein, or by modulating the transcription or translation of an SMP nucleic acid molecule of the invention.

Another aspect of the invention pertains to a method for producing a fine 25 chemical. This method involves the culturing of a cell containing a vector directing the expression of an SMP nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector 30 directing the expression of an SMP nucleic acid. In another preferred embodiment, this method further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus *Corynebacterium* or *Brevibacterium*, or is selected from those strains set forth in Table 3.

Another aspect of the invention pertains to methods for modulating production of a molecule from a microorganism. Such methods include contacting the cell with an

agent which modulates SMP protein activity or SMP nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent. In a preferred embodiment, the cell is modulated for one or more *C. glutamicum* carbon metabolism pathways or for the production of energy through processes such as 5 oxidative phosphorylation, such that the yields or rate of production of a desired fine chemical by this microorganism is improved. The agent which modulates SMP protein activity can be an agent which stimulates SMP protein activity or SMP nucleic acid expression. Examples of agents which stimulate SMP protein activity or SMP nucleic acid expression include small molecules, active SMP proteins, and nucleic acids 10 encoding SMP proteins that have been introduced into the cell. Examples of agents which inhibit SMP activity or expression include small molecules and antisense SMP nucleic acid molecules.

Another aspect of the invention pertains to methods for modulating yields of a desired compound from a cell, involving the introduction of a wild-type or mutant SMP gene into a cell, either maintained on a separate plasmid or integrated into the genome of 15 the host cell. If integrated into the genome, such integration can be random, or it can take place by homologous recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated. In a preferred embodiment, said yields are increased. In another preferred 20 embodiment, said chemical is a fine chemical. In a particularly preferred embodiment, said fine chemical is an amino acid. In especially preferred embodiments, said amino acid is L-lysine.

Detailed Description of the Invention

25 The present invention provides SMP nucleic acid and protein molecules which are involved in the metabolism of carbon compounds such as sugars and the generation of energy molecules by processes such as oxidative phosphorylation in *Corynebacterium glutamicum*. The molecules of the invention may be utilized in the modulation of production of fine chemicals from microorganisms, such as *C. glutamicum*, either directly (e.g., where overexpression or optimization of a glycolytic 30 pathway protein has a direct impact on the yield, production, and/or efficiency of production of, e.g., pyruvate from modified *C. glutamicum*), or may have an indirect

5 impact which nonetheless results in an increase of yield, production, and/or efficiency of production of the desired compound (e.g., where modulation of proteins involved in oxidative phosphorylation results in alterations in the amount of energy available to perform necessary metabolic processes and other cellular functions, such as nucleic acid and protein biosynthesis and transcription/translation). Aspects of the invention are further explicated below.

I. Fine Chemicals

The term 'fine chemical' is art-recognized and includes molecules produced by 10 an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described e.g. in Kuninaka, A. (1996) Nucleotides and 15 related compounds, p. 561-612, in Biotechnology vol. 6, Rehm *et al.*, eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (e.g., arachidonic acid), diols (e.g., propane diol, and butane diol), carbohydrates (e.g., hyaluronic acid and trehalose), aromatic compounds (e.g., aromatic amines, 20 vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and 25 Technological Associations in Malaysia, and the Society for Free Radical Research - Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane *et al.* (1998) *Science* 282: 63-68), and all other chemicals described in Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below.

30 A. *Amino Acid Metabolism and Uses*

Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term "amino acid" is art-

recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ullmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L-amino acids are generally the only type found in naturally-occurring proteins.

5 Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. Biochemistry, 3rd edition, pages 578-590 (1988)). The 'essential' amino acids

10 (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 'nonessential' amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals

15 do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.

Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, 20 valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/L-methionine are common feed additives. (Leuchtenberger, W. (1996) Amino acids – technical production and use, p. 466-502 in Rehm *et al.* (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be 25 useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others.

described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.

The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial 5 amino acid biosynthesis and regulation thereof, see Umbarger, H.E. (1978) *Ann. Rev. Biochem.* 47: 533-606). Glutamate is synthesized by the reductive amination of α -ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three-step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and 10 resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain β -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase. Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate 15 pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all 20 biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.

25 Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. *Biochemistry* 3rd ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle" p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in 30 terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own

production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L. Biochemistry, 3rd ed. Ch. 24: "Biosynthesis of Amino Acids and Heme" p. 575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell.

5

B. Vitamin, Cofactor, and Nutraceutical Metabolism and Uses

Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are 10 either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications 15 of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art-recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins 20 may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such 25 molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).

The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and 30 Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological

methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave SMP mRNA transcripts to thereby inhibit translation of SMP mRNA. A ribozyme having specificity for an SMP-encoding nucleic acid can be designed based upon the nucleotide sequence of an SMP cDNA disclosed herein (i.e., SEQ ID NO. 3 (RXA01626)). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an SMP-encoding mRNA. See, e.g., Cech *et al.* U.S. Patent No. 4,987,071 and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, SMP mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

Alternatively, SMP gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an SMP nucleotide sequence (e.g., an SMP promoter and/or enhancers) to form triple helical structures that prevent transcription of an SMP gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

25 B. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an SMP protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of

autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector.

10 However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells. Preferred regulatory sequences are, for example, promoters such as cos-, tac-, trp-, tet-, trp-tet-, lpp-, lac-, lpp-lac-, lacI^q-, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, arny, SPO2, λ-Pr- or λ P_L, which are used preferably in bacteria. Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as ADC1, MFα, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH, promoters from plants such as CaMV/3SS, SSU, OCS, lib4,

usp, STLS1, B33, nos or ubiquitin- or phaseolin-promoters. It is also possible to use artificial promoters. It will be appreciated by those of ordinary skill in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., SMP proteins, mutant forms of SMP proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of SMP proteins in prokaryotic or eukaryotic cells. For example, SMP genes can be expressed in bacterial cells such as *C. glutamicum*, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M.A. *et al.* (1992) "Foreign gene expression in yeast: a review", *Yeast* 8: 423-488; van den Hondel, C.A.M.J.J. *et al.* (1991) "Heterologous gene expression in filamentous fungi" in: More Gene Manipulations in Fungi, J.W. Bennet & L.L. Lasure, eds., p. 396-428: Academic Press: San Diego; and van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, Peberdy, J.F. *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge), algae and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988) High efficiency *Agrobacterium tumefaciens* -mediated transformation of *Arabidopsis thaliana* leaf and cotyledon explants" *Plant Cell Rep.* 583-586), or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein but also to the C-terminus or fused within suitable regions in the proteins. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion

expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

5 Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the SMP protein is cloned into a 10 pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant SMP protein unfused to GST can be recovered by cleavage of the fusion protein with thrombin.

15 Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315), pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHs1, pHs2, pPLc236, pMBL24, pLG200, pUR290, pIN-III113-B1, λgt11, pBdCl, and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89; and 20 Pouwels *et al.*, cds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by 25 host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected. For example, the plasmids pIJ101, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming *Streptomyces*, while plasmids pUB110, pC194, or pBD214 are suited for transformation 30 of *Bacillus* species. Several plasmids of use in the transfer of genetic information into *Corynebacterium* include pHM1519, pBL1, pSA77, or pAJ667 (Pouwels *et al.*, eds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018).

One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another 5 strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as *C. glutamicum* (Wada *et al.* (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

10 In another embodiment, the SMP protein expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYEPSec1 (Baldari, *et al.*, (1987) *Embo J.* 6:229-234), 2 μ , pAG-1, Yep6, Yep13, pEMBLYe23, pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Vectors and 15 methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J.F. Peberdy, *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge, and Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: 20 New York (ISBN 0 444 904018).

Alternatively, the SMP proteins of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) 25 *Virology* 170:31-39).

In another embodiment, the SMP proteins of the invention may be expressed in unicellular plant cells (such as algae) or in plant cells from higher plants (e.g., the spermatophytes, such as crop plants). Examples of plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New 30 plant binary vectors with selectable markers located proximal to the left border", *Plant Mol. Biol.* 20: 1195-1197; and Bevan, M.W. (1984) "Binary *Agrobacterium* vectors for plant transformation", *Nucl. Acid. Res.* 12: 8711-8721, and include pLGV23, pGHIac+,

pBIN19, pAK2004, and pDH51 (Pouwels *et al.*, eds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in

a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to SMP mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. et al., *Antisense RNA as a molecular tool for genetic analysis, Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, an SMP protein can be expressed in bacterial cells such as *C. glutamicum*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to one of ordinary skill in the art. Microorganisms related to *Corynebacterium glutamicum* which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection", "conjugation" and "transduction" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid,

transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, chemical-mediated transfer, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an SMP protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by, for example, drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

the selectable marker gene will survive, while the SMP gene will not. To create a homologous recombinant microorganism, a vector is prepared which contains at least a portion of an SMP gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the SMP gene. 20 Preferably, this SMP gene is a *Corynebacterium glutamicum* SMP gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous SMP gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, 25 the vector can be designed such that, upon homologous recombination, the endogenous SMP gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous SMP protein). In the homologous recombination vector, the altered portion 30 of the SMP gene is flanked at its 5' and 3' ends by additional nucleic acid of the SMP gene to allow for homologous recombination to occur between the exogenous SMP gene carried by the vector and an endogenous SMP gene in a microorganism. The additional

flanking SMP nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas, K.R., and Capecchi, M.R. (1987) *Cell* 51: 503 for a description of homologous recombination vectors). The vector is introduced into a microorganism (e.g., by electroporation) and cells in which the introduced SMP gene has homologously recombined with the endogenous SMP gene are selected, using art-known techniques.

In another embodiment, recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene. 10 For example, inclusion of an SMP gene on a vector placing it under control of the lac operon permits expression of the SMP gene only in the presence of IPTG. Such regulatory systems are well known in the art.

In another embodiment, an endogenous SMP gene in a host cell is disrupted (e.g., by homologous recombination or other genetic means known in the art) such that 15 expression of its protein product does not occur. In another embodiment, an endogenous or introduced SMP gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional SMP protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an SMP gene in a microorganism has been altered (e.g., by deletion, 20 truncation, inversion, or point mutation) such that the expression of the SMP gene is modulated. One of ordinary skill in the art will appreciate that host cells containing more than one of the described SMP gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention.

25 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an SMP protein. Accordingly, the invention further provides methods for producing SMP proteins using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding an SMP protein has 30 been introduced, or into which genome has been introduced a gene encoding a wild-type or altered SMP protein) in a suitable medium until SMP protein is produced. In another

embodiment, the method further comprises isolating SMP proteins from the medium or the host cell.

C. Isolated SMP Proteins

5 Another aspect of the invention pertains to isolated SMP proteins, and biologically active portions thereof. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes 10 preparations of SMP protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of SMP protein having less than about 30% (by dry weight) of non-SMP protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-SMP protein, 15 still more preferably less than about 10% of non-SMP protein, and most preferably less than about 5% non-SMP protein. When the SMP protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein 20 preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of SMP protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of SMP protein having less than about 30% (by dry weight) of chemical precursors or non-SMP chemicals, more preferably less than about 20% chemical precursors or non-SMP chemicals, still more preferably less than about 10% chemical precursors or non-SMP chemicals, and most preferably less than about 5% chemical precursors or non-SMP chemicals. In preferred embodiments, 25 isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the SMP protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a *C. glutamicum* SMP protein in a 30 microorganism such as *C. glutamicum*.

frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify SMP homologues (Arkin and Yourvan (1992) *PNAS* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

5 In another embodiment, cell based assays can be exploited to analyze a variegated SMP library, using methods well known in the art.

D. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the 10 following methods: identification of *C. glutamicum* and related organisms; mapping of genomes of organisms related to *C. glutamicum*; identification and localization of *C. glutamicum* sequences of interest; evolutionary studies; determination of SMP protein regions required for function; modulation of an SMP protein activity; modulation of the metabolism of one or more sugars; modulation of high-energy molecule production in a 15 cell (i.e., ATP, NADPH); and modulation of cellular production of a desired compound, such as a fine chemical.

The SMP nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof. Also, they may be used to identify the presence of *C. glutamicum* 20 or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain whether this organism is present. 25 Although *Corynebacterium glutamicum* itself is nonpathogenic, it is related to pathogenic species, such as *Corynebacterium diphtheriae*. *Corynebacterium diphtheriae* is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology. In this disease, a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli 30 secrete toxin which is disseminated through this lesion to distal susceptible tissues of the body. Degenerative changes brought about by the inhibition of protein synthesis in these tissues, which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and

spleen, result in the systemic pathology of the disease. Diphtheria continues to have high incidence in many parts of the world, including Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria in the latter two regions has resulted in at least 5,000 deaths since 1990.

5 In one embodiment, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth as odd-numbered or even-numbered SEQ ID NOs, respectively, in the Sequence Listing) in a subject, thereby detecting the presence or activity of

10 *Corynebacterium diphtheriae* in the subject. *C. glutamicum* and *C. diphtheriae* are related bacteria, and many of the nucleic acid and protein molecules in *C. glutamicum* are homologous to *C. diphtheriae* nucleic acid and protein molecules, and can therefore be used to detect *C. diphtheriae* in a subject.

15 The nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of *C. glutamicum* proteins. For example, to identify the region of the genome to which a particular *C. glutamicum* DNA-binding protein binds, the *C. glutamicum* genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of *C. glutamicum*, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds. Further, the nucleic acid molecules of the

20 invention may be sufficiently homologous to the sequences of related species such that these nucleic acid molecules may serve as markers for the construction of a genomic map in related bacteria, such as *Brevibacterium lactofermentum*.

25

30 The SMP nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The metabolic and energy-releasing processes in which the molecules of the invention participate are utilized by a wide variety of prokaryotic and eukaryotic cells; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the

evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type of determination is of value for protein 5 engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function.

Manipulation of the SMP nucleic acid molecules of the invention may result in the production of SMP proteins having functional differences from the wild-type SMP 10 proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.

15 The invention provides methods for screening molecules which modulate the activity of an SMP protein, either by interacting with the protein itself or a substrate or binding partner of the SMP protein, or by modulating the transcription or translation of an SMP nucleic acid molecule of the invention. In such methods, a microorganism expressing one or more SMP proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression 20 of the SMP protein is assessed.

There are a number of mechanisms by which the alteration of an SMP protein of the invention may directly affect the yield, production, and/or efficiency of production 25 of a fine chemical from a *C. glutamicum* strain incorporating such an altered protein. The degradation of high-energy carbon molecules such as sugars, and the conversion of compounds such as NADH and FADH₂ to more useful forms via oxidative phosphorylation results in a number of compounds which themselves may be desirable fine chemicals, such as pyruvate, ATP, NADH, and a number of intermediate sugar 30 compounds. Further, the energy molecules (such as ATP) and the reducing equivalents (such as NADH or NADPH) produced by these metabolic pathways are utilized in the cell to drive reactions which would otherwise be energetically unfavorable. Such unfavorable reactions include many biosynthetic pathways for fine chemicals. By improving the ability of the cell to utilize a particular sugar (e.g., by manipulating the genes encoding enzymes involved in the degradation and conversion of that sugar into energy for the cell), one may increase the amount of energy available to permit

unfavorable, yet desired metabolic reactions (e.g., the biosynthesis of a desired fine chemical) to occur.

Further, modulation of one or more pathways involved in sugar utilization permits optimization of the conversion of the energy contained within the sugar molecule to the production of one or more desired fine chemicals. For example, by reducing the activity of enzymes involved in, for example, gluconeogenesis, more ATP is available to drive desired biochemical reactions (such as fine chemical biosyntheses) in the cell. Also, the overall production of energy molecules from sugars may be modulated to ensure that the cell maximizes its energy production from each sugar molecule. Inefficient sugar utilization can lead to excess CO₂ production and excess energy, which may result in futile metabolic cycles. By improving the metabolism of sugar molecules, the cell should be able to function more efficiently, with a need for fewer carbon molecules. This should result in an improved fine chemical product: sugar molecule ratio (improved carbon yield), and permits a decrease in the amount of sugars that must be added to the medium in large-scale fermentor culture of such engineered *C. glutamicum*.

The mutagenesis of one or more SMP genes of the invention may also result in SMP proteins having altered activities which indirectly impact the production of one or more desired fine chemicals from *C. glutamicum*. For example, by increasing the efficiency of utilization of one or more sugars (such that the conversion of the sugar to useful energy molecules is improved), or by increasing the efficiency of conversion of reducing equivalents to useful energy molecules (e.g., by improving the efficiency of oxidative phosphorylation, or the activity of the ATP synthase), one can increase the amount of these high-energy compounds available to the cell to drive normally unfavorable metabolic processes. These processes include the construction of cell walls, transcription, translation, and the biosynthesis of compounds necessary for growth and division of the cells (e.g., nucleotides, amino acids, vitamins, lipids, etc.) (Lengeler *et al.* (1999) *Biology of Prokaryotes*, Thieme Verlag: Stuttgart, p. 88-109; 913-918; 875-899). By improving the growth and multiplication of these engineered cells, it is possible to increase both the viability of the cells in large-scale culture, and also to improve their rate of division, such that a relatively larger number of cells can survive in fermentor culture. The yield, production, or efficiency of production may be increased, at least

due to the presence of a greater number of viable cells, each producing the desired fine chemical.

Further, many of the degradation products produced during sugar metabolism are themselves utilized by the cell as precursors or intermediates for the production of a number of other useful compounds, some of which are fine chemicals. For example, 5 pyruvate is converted into the amino acid alanine, and ribose-5-phosphate is an integral part of, for example, nucleotide molecules. The amount and efficiency of sugar metabolism, then, has a profound effect on the availability of these degradation products in the cell. By increasing the ability of the cell to process sugars, either in terms of 10 efficiency of existing pathways (e.g., by engineering enzymes involved in these pathways such that they are optimized in activity), or by increasing the availability of the enzymes involved in such pathways (e.g., by increasing the number of these enzymes present in the cell), it is possible to also increase the availability of these degradation products in the cell, which should in turn increase the production of many 15 different other desirable compounds in the cell (e.g., fine chemicals).

The aforementioned mutagenesis strategies for SMP proteins to result in increased yields of a fine chemical from *C. glutamicum* are not meant to be limiting; variations on these strategies will be readily apparent to one of ordinary skill in the art. Using such strategies, and incorporating the mechanisms disclosed herein, the nucleic 20 acid and protein molecules of the invention may be utilized to generate *C. glutamicum* or related strains of bacteria expressing mutated SMP nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved. This desired compound may be any product produced by *C. glutamicum*, 25 which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of *C. glutamicum*, but which are produced by a *C. glutamicum* strain of the invention.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, 30 published patent applications, Tables, and the sequence listing cited throughout this application are hereby incorporated by reference.

TABLE 1: GENES IN THE APPLICATION

HMP:

<u>Nucleic Acid</u>	<u>Amino Acid</u>	<u>Identification Code</u>	<u>Contig:</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
<u>SEQ ID NO</u>	<u>SEQ ID NO</u>					
1	2	RXSO2735	W0074	14576	15280	8-Phosphoglucofuranose 4-epimerase
3	4	RXA01628	GR00452	4270	3826	L-ribulose-phosphate 3-EPIMERASE (EC 5.1.3.1)
5	6	RXA02245	GR00854	13639	14296	RIBULOSE-PHOSPHATE ISOMERASE (EC 5.3.1.6)
7	8	RXA01016	GR00290	348	5	RIBOSE-5-PHOSPHATE ISOMERASE (EC 5.3.1.6)

TCA:

<u>Nucleic Acid</u>	<u>Amino Acid</u>	<u>Identification Code</u>	<u>Contig:</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
<u>SEQ ID NO</u>	<u>SEQ ID NO</u>					
9	10	RXN01312	W0082	20803	18785	SUCCINATE DEHYDROGENASE FLAVOPROTEIN SUBUNIT (EC 1.3.98.1)
11	12	FRXA01312	GR00390	2890	1814	SUCCINATE DEHYDROGENASE FLAVOPROTEIN SUBUNIT (EC 1.3.98.1)
13	14	RXN00231	WV0083	15484	14015	SUCCINATE-SEMIALDEHYDE DEHYDROGENASE (NADP ⁺) (EC 1.2.1.16)
15	16	RXA01311	GR00380	1611	885	SUCCINATE DEHYDROGENASE IRON-SULFUR PROTEIN (EC 1.3.99.1)
17	18	RXA01535	GR00427	1354	2780	FUMARATE HYDRATASE PRECURSOR (EC 4.2.1.2)
19	20	RXA00517	GR00131	1407	2447	MALATE DEHYDROGENASE (EC 1.1.1.37) (EC 1.1.1.82)
21	22	RXA01350	GR00382	1844	2827	MALATE DEHYDROGENASE (EC 1.1.1.37)

EMB-Pathway

<u>Nucleic Acid</u>	<u>Amino Acid</u>	<u>Identification Code</u>	<u>Contig:</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
<u>SEQ ID NO</u>	<u>SEQ ID NO</u>					
23	24	RXA02149	GR00839	17786	18754	GLUCOKINASE (EC 2.7.1.2)
25	28	RXA01814	GR00615	2571	910	PHOSPHOGLUCOMUTASE (EC 5.4.2.2) / PHOSPHOMANNOMUTASE
27	28	RXN02803	WV0088	1	657	PHOSPHOGLUCOMUTASE (EC 5.4.2.2) / PHOSPHOMANNOMUTASE
29	30	FRXA02803	GR00784	2	400	PHOSPHOGLUCOMUTASE (EC 5.4.2.2) / PHOSPHOMANNOMUTASE
31	32	RXN03076	WV0043	1824	35	PHOSPHOGLUCOMUTASE (EC 5.4.2.2) / PHOSPHOMANNOMUTASE
33	34	FRXA02854	GR10002	1588	5	PHOSPHOGLUCOMUTASE (EC 5.4.2.2) / PHOSPHOMANNOMUTASE
35	36	RXA00511	GR00129	1	513	PHOSPHOGLUCOMUTASE (EC 5.4.2.2) / PHOSPHOMANNOMUTASE

Table 1 (continued)

Nucleic Acid SEQ ID NO	Identification Code	Contig	NT Start	NT Stop	Function
37	F RXA01385	W0091	1476	103	PHOSPHOGLUCOMUTASE (EC 5.4.2.2) / PHOSPHOMANNOMUTASE (EC 5.4.2.8)
38	40	F RXA01385	GR00397	897	4
39	41	RXA00098	GR00014	8525	8144
	43	RXA01988	GR00578	1	830
	44	RXA00340	GR00059	1549	2694
	46	RXA02492	GR00720	2201	2917
	48	RXA00381	GR00882	1451	846
	49	RXA02122	GR00836	6511	5813
	50	RXA00208	GR00032	6171	5134
	51	RXA01243	GR00359	2302	3281
	53	RXA01882	GR00538	1165	2154
	55	RXA01702	GR00479	1397	366
	57	RXA02258	GR00834	28451	27227
	59	RXA01225	W0064	6382	4943
	61	RXA01225	GR00354	5302	6741
	63	F RXA01225	GR00654	23934	24935
	65	RXA02258	GR00654	25155	26399
	67	RXA02257	GR00036	2365	1091
	69	RXA00735	GR00306	1552	122
	71	RXA01083	W0098	72801	70945
	73	RXA02675	GR00764	2	384
	75	F RXA02875	GR00755	2849	4370
	77	F RXA02695	GR00179	5289	3401
	79	RXA00682	GR00179	8440	5349
	81	RXA00683	W0135	22708	20972
	83	RXN00635	GR00788	88	662
	85	F RXA02807	GR00167	3	923
	87	F RXA00835	W00119	1391	2221
	89	RXN03044	GR00852	3	281
	91	F RXA02852	GR00041	126	965
	93	F RXA02688	W0049	2243	2850
	95	RXN03088	GR10022	411	4
	97	F RXA02887	W0019	1	1362
	99	RXN03043	GR10039	1291	5
	101	F RXA02897	W0047	88	1110
	103	RXN03083	GR10001	89	1496
	105	F RXA02853	GR00654	27401	30172
	106	RXA02259	W0047	4500	5315
	107	RXN02328	GR00688	5338	4523
	109	F RXA02326	W0047	3533	4492
	111	RXN02327	GR00688	6306	6346
	113	F RXA02327	W0047	1842	3437
	115	RXN02328	GR00688	7783	8401
	117	F RXA02328	W0079	11316	11316
	119	F RXA02328	RXN01048	122	124
	121				123

Table 1 (continued)

Nucleic Acid SEQ ID NO	Amino Acid SEQ ID NO	Identification Code	Contd.	NT Start	NT Stop	Function
126	F RXA01048	GR00298		3	290	MALIC ENZYME (EC 1.1.1.39)
127	F RXA00290	GR0046		4693	5655	MALIC ENZYME (EC 1.1.1.39)
128	RXA02894	GR00755		1879	2820	L-LACTATE DEHYDROGENASE (CYTOCHROME) (EC 1.1.2.4)
129	RXN00286	WV0176		35783	38608	D-LACTATE DEHYDROGENASE (CYTOCHROME) (EC 1.1.2.4)
131	F RXA0286	GR00046		3	2837	D-LACTATE DEHYDROGENASE (CYTOCHROME) (EC 1.1.2.3)
132	F RXA01901	GR00544		4158	5417	L-LACTATE DEHYDROGENASE (CYTOCHROME) (EC 1.1.2.3)
133	RXN01852	WV0105		9854	11688	D-LACTATE DEHYDROGENASE (EC 1.1.1.28)
135	RXN01852	GR00562		1	218	D-LACTATE DEHYDROGENASE (EC 1.1.1.28)
137	RXN01852	GR00562		4611	6209	D-LACTATE DEHYDROGENASE DEHYDROGENASE (EC 1.1.1.95)
138	F RXA01952	GR00047		2845	1734	D-3-PHOSPHOGLYCERATE DEHYDROGENASE (EC 1.1.1.95)
139	F RXA01955	WV0157		6138	5538	D-3-PHOSPHOGLYCERATE DEHYDROGENASE (EC 1.1.1.95)
141	RXA00293	GR00315		2	304	D-3-PHOSPHOGLYCERATE DEHYDROGENASE (EC 1.1.1.95)
142	RXN01130	WV0085		509	6	D-3-PHOSPHOGLYCERATE DEHYDROGENASE (EC 1.1.1.95)
143	F RXA01130	GR00316		568	1116	D-3-PHOSPHOGLYCERATE DEHYDROGENASE (EC 1.1.1.95)
144	RXN03112	WV0127		3127	2240	IOLB PROTEIN: D-FRUCTOSE 1,6-BISPHOSPHATE + GLYCERONE-CC
145	RXN03112	GR00239		2344	3207	IOLB PROTEIN: D-GLYCERALDEHYDE 3-PHOSPHATE
146	F RXA00871	GR00239				PHOSPHATE + D-GLYCERALDEHYDE 3-PHOSPHATE
147	F RXA00871					IOLS PROTEIN
149	150	RXN02829		287	559	IOLS PROTEIN
151	152	F RXA02829		287	562	NAGD PROTEIN
153	154	RXN01488		7474	8298	PUTATIVE N-GLYCERALDEHYDE 2-PHOSPHOTRANSFERASE
155	156	F RXA01488		1250	2074	PUTATIVE N-GLYCERALDEHYDE 2-PHOSPHOTRANSFERASE
157	158	RXN01488		3993	2989	GLPX PROTEIN
159	160	F RXA01488		6135	5224	D-3-PHOSPHOGLYCERATE DEHYDROGENASE (EC 1.1.1.95)
161	162	RXA00794		1380	686	D-3-PHOSPHOGLYCERATE DEHYDROGENASE (EC 1.1.1.95)
163	164	RXN02920		59053	58385	PHOSPHOGLYCERATE MUTASE (EC 5.4.2.1)
165	166	F RXA02379		3216	3428	PYRUVATE CARBOXYLASE (EC 6.4.1.1)
167	168	RXN02688		3110	519	PYRUVATE DEHYDROGENASE E1 COMPONENT (EC 1.2.4.1)
169	170	RXN03087		3	281	PYRUVATE DEHYDROGENASE E1 COMPONENT (EC 1.2.4.1)
171	172	RXN03188		14370	12541	PHOSPHOENOLPYRUVATE CARBOXYKINASE [GTP] (EC 4.1.1.32)
173	174	RXN03187		3477	2298	LIPOAMIDE DEHYDROGENASE COMPONENT (E3) OF BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX (EC 1.8.1.4)
175	176	RXN02581		WV0009		CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPONENT (E3) OF BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX (EC 1.8.1.4)
177	178	RXN01280				LIPOAMIDE DEHYDROGENASE COMPONENT (E3) OF BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX (EC 1.8.1.4)
179	180					CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX (EC 1.8.1.4)
181	182	RXS01261		WV0009	3703	3533
183	184					CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX (EC 1.8.1.4)
Glycerol metabolism						
Nucleic Acid SEQ ID NO	Amino Acid SEQ ID NO	Identification Code	Contd.	NT Start	NT Stop	Function
185	186	RXA02640		GR00749	1400	GLYCEROL KINASE (EC 2.7.1.30)
187	188	RXN01025		WV0143	5483	GLYCEROL-3-PHOSPHATE DEHYDROGENASE (NAD(P)+) (EC 1.1.1.94)
189	190	FRXA01026		GR00293	939	GLYCEROL-3-PHOSPHATE DEHYDROGENASE (NAD(P)+) (EC 1.1.1.94)
191	192	RXA01851		GR00055	3515	AEROBIC GLYCEROL-3-PHOSPHATE DEHYDROGENASE (EC 1.1.99.5)
193	194	RXA01242		GR00358	1528	GLYCEROL-3-PHOSPHATE REGULON REPRESSOR
195	196	RXA02288		GR00681	992	GLYCEROL-3-PHOSPHATE REGULON REPRESSOR

Table 1 (continued)

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contd.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
197	198	RXN01891	W0122	24949	24086	GLYCEROL-3-PHOSPHATE-BINDING PERIPLASMIC PROTEIN PRECURSOR
199	200	F RXA01891	GR00541	1738	918	GLYCEROL-3-PHOSPHATE-BINDING PERIPLASMIC PROTEIN PRECURSOR
201	202	RXA02414	GR00703	3808	3082	Uncharacterized protein involved in glycerol metabolism (homolog of <i>Drosophila rhomboid</i>)
203	204	RXN01580	W0122	2291	22027	Glycophosphoryl diester phosphodiesterase

Acetate metabolism

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contd.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
205	206	RXA01436	GRO0418	2547	1357	ACETATE KINASE (EC 2.7.2.1)
		RXA00588	GRO0179	8744	7941	ACETATE OPERON REPRESSOR
207	208	RXA02468	GR00337	4426	3391	ALCOHOL DEHYDROGENASE (EC 1.1.1.1)
209	210	RXA01571	GR00438	1380	1959	ALCOHOL DEHYDROGENASE (EC 1.1.1.1)
211	212	RXA01572	GR00438	1928	2419	ALCOHOL DEHYDROGENASE (EC 1.1.1.1)
213	214	RXA01758	GR00498	3861	2945	ALCOHOL DEHYDROGENASE (EC 1.1.1.1)
215	216	RXA02539	GR00728	11676	10158	ALDEHYDE DEHYDROGENASE (EC 1.2.1.3)
217	218	RXN03081	W0034	108	437	ALDEHYDE DEHYDROGENASE (EC 1.2.1.3)
219	220	RXN03150	W0155	10878	10056	ALDEHYDE DEHYDROGENASE (EC 1.2.1.3)
221	222	RXN01340	W0033	3	860	ALDEHYDE DEHYDROGENASE (EC 1.2.1.3)
223	224	RXN01498	W0008	1598	3160	ALDEHYDE DEHYDROGENASE (EC 1.2.1.3)
225	226	RXN02674	W0315	15814	14163	ACETOLACTATE SYNTHASE LARGE SUBUNIT (EC 4.1.3.18)
227	228	RXN00888	W0127	2230	320	ACETOLACTATE SYNTHASE LARGE SUBUNIT (EC 4.1.3.18)
229	230	RXN01143	W0077	9372	8254	ACETOLACTATE SYNTHASE LARGE SUBUNIT (EC 4.1.3.18)
231	232	RXN01148	W0284	243	835	ACETOLACTATE SYNTHASE SMALL SUBUNIT (EC 4.1.3.18)
233	234	RXN01144	W0077	8237	7722	ACETOLACTATE SYNTHASE SMALL SUBUNIT (EC 4.1.3.18)
235	236					

Butanediol, diacetyl and acetoin formation

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contd.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
237	238	RXA02474	GR00715	8082	7309	(S,S)-butane-2,3-diol dehydrogenase (EC 1.1.1.76)
239	240	RXA02453	GR00710	8103	5351	ACETOIN(DIACETYL) REDUCTASE (EC 1.1.1.5)
241	242	RXN01758	W0112	27383	28399	ALCOHOL DEHYDROGENASE (EC 1.1.1.1)

Table 1 (continued)

HMP-Cycle						
<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
243 244	RXA022737	GR00763	3312	1771	GLUCOSE-6-PHOSPHATE 1-DEHYDROGENASE (EC 1.1.1.49)	
245 246	RXA022738	GR00763	4498	3420	TRANSALDOLASE (EC 2.2.1.2)	
247 248	RXA022739	GR00763	6789	4670	TRANSKETOLASE (EC 2.2.1.1)	
249	RXA00985	GR00270	1232	510	6-PHOSPHOGLUCONATE DEHYDROGENASE, DECARBOXYLATING (EC 1.1.1.44)	
251	252	RXN00899	W0108	2817	1388	6-PHOSPHOGLUCONATE DEHYDROGENASE, DECARBOXYLATING (EC 1.1.1.44)
253	254	F RXA00899	GR00263	3012	4448	6-PHOSPHOGLUCONATE DEHYDROGENASE, DECARBOXYLATING (EC 1.1.1.44)

Nucleotide sugar conversion						
<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
256	258	RXN02598	W0098	48784	47582	UDP-GALACTOPYRANOSE MUTASE (EC 5.4.99.9)
267	268	F RXA02696	GR00742	1	489	UDP-GALACTOPYRANOSE MUTASE (EC 5.4.99.9)
259	260	F RXA02642	GR00749	5383	5880	UDP-GALACTOPYRANOSE MUTASE (EC 5.4.99.9)
261	262	RXA02572	GR00737	2	846	UDP-GLUCOSE 6-DEHYDROGENASE (EC 1.1.1.22)
263	264	RXA02485	GR00718	2345	3445	UDP-N-ACETYLGLUCOSAMINE REDUCTASE (EC 1.1.1.168)
265	266	RXA01216	GR00352	2302	1202	UDP-N-ACETYLGLUCOSAMINE PYROPHOSPHORYLASE (EC 2.7.7.23)
267	268	RXA01259	GR00367	987	130	UTP-GLUCOSE-1-PHOSPHATE URIDYLYLTRANSFERASE (EC 2.7.7.9)
269	270	RXA02028	GR00816	573	998	UTP-GLUCOSE-1-PHOSPHATE URIDYLYLTRANSFERASE (EC 2.7.7.9)
271	272	RXA01262	GR00387	6351	7191	GDP-MANNOSE 6-DEHYDROGENASE (EC 2.7.7.13)
273	274	RXA01377	GR00400	3995	5020	MANNOSE-1-PHOSPHATE GUANYLYLTRANSFERASE (EC 2.7.7.27)
275	276	RXA02083	GR00626	3301	4527	GLUCOSE-1-PHOSPHATE ADENYLYLTRANSFERASE (EC 2.7.7.24)
277	278	RXN00014	W0048	8848	8827	GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (EC 2.7.7.24)
279	280	F RXA00014	GR00002	4448	5227	GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE (EC 2.7.7.24)
281	282	RXA01570	GR00438	427	1281	D-RIBITOL-5-PHOSPHATE CYTIDYLYLTRANSFERASE (EC 2.7.7.40)
283	284	RXA02868	GR00763	7280	8483	DTDP-GLUCOSE 4- β -DEHYDRATASE (EC 4.2.1.49)
285	286	RXA00825	GR00222	22	1154	

Inositol and ribitol metabolism						
<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
287	288	RXA01887	GR00539	4219	3209	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)

Table 1 (continued)

Nucleic Acid	Amino Acid	Identification Code	Contd.	NT Start	NT Stop	Function
SEQ ID NO	SEQ ID NO					
289	290	RXN00013	WV0048	7966	8838	MYO-INOSITOL-1(OR 4)-MONOPHOSPHATASE 1 (EC 3.1.3.25)
291	292	F RXA00013	GR00002	3568	4438	MYO-INOSITOL-1(OR 4)-MONOPHOSPHATASE 1 (EC 3.1.3.25)
293	294	RXA01099	GR00306	6328	5904	INOSITOL MONOPHOSPHATE PHOSPHATASE
295	296	RXN01332	WV0273	579	4	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)
297	298	F RXA01332	GR00388	652	4	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)
299	300	RXA01632	GR00454	2338	3342	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)
301	302	RXA01633	GR00454	3380	4462	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)
303	304	RXN01406	WV0278	2898	1977	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)
305	306	RXN01630	WV0050	48113	47037	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)
307	308	RXN00528	WV0079	23408	22318	MYO-INOSITOL 1-PHOSPHATE SYNTHASE (EC 5.5.1.4)
309	310	RXN03657	WV0028	7017	7898	MYO-INOSITOL 2-DEHYDROGENASE (EC 1.1.1.18)
311	312	F RXA02902	GR10040	10277	10948	GLUCOSE-FRUCTOSE OXIDOREDUCTASE PRECURSOR (EC 1.1.99.28)
313	314	RXA00231	GR00038	931	224	RIBITOL 2-DEHYDROGENASE (EC 1.1.1.58)

Utilization of sugars

Nucleic Acid	Amino Acid	Identification Code	Contd.	NT Start	NT Stop	Function
SEQ ID NO	SEQ ID NO					
316	316	RXN02654	WV0090	12206	13090	GLUCOSE 1-DEHYDROGENASE (EC 1.1.1.47)
317	316	F RXA02654	GR00752	7405	8289	GLUCOSE 1-DEHYDROGENASE II (EC 1.1.1.47)
319	320	RXN01049	WV0078	9833	11114	GLUCONOKINASE (EC 2.7.1.12)
321	322	F RXA01049	GR00286	1502	492	GLUCONOKINASE (EC 2.7.1.12)
323	324	F RXA01050	GR00296	1972	1499	GLUCONOKINASE (EC 2.7.1.12)
325	326	RXA00202	GR00032	1216	275	D-RIBOSE-BINDING PERPLASMIC PROTEIN PRECURSOR
327	328	RXN00872	WV0127	6567	5604	FRUCTOKINASE (EC 2.7.1.4)
329	330	F RXA00872	GR00240	965	1086	PERPLASMIC BETA-GLUCOSIDASE/BETA-XYLOSIDASE PRECURSOR
331	332	RXN00799	WV0039	59477	58834	(EC 3.2.1.21) (EC 3.2.1.37)
333	334	F RXA00799	GR00214	1	1584	PERPLASMIC BETA-GLUCOSIDASE/BETA-XYLOSIDASE PRECURSOR
335	336	RXA00032	GR00003	12028	10520	(EC 3.2.1.21) (EC 3.2.1.37)
337	338	RXA02528	GR00725	6880	7854	MANNITOL 2-DEHYDROGENASE (EC 1.1.1.67)
339	340	RXN00316	WV0008	7035	8180	FRUCTOSE REDUCTASE (EC 1.1.1.1)
341	342	F RXA00309	GR00053	316	5	Hypothetical Oxidoreductase (EC 1.1.1.1)
343	344	RXN00310	WV0008	8616	7750	GLUCOSE-FRUCTOSE OXIDOREDUCTASE PRECURSOR (EC 1.1.99.28)
345	346	F RXA00310	GR00053	735	301	GLUCOSE-FRUCTOSE OXIDOREDUCTASE PRECURSOR (EC 1.1.99.28)
347	348	RXA00041	GR00007	1248	5	SUCROSE-6-PHOSPHATE HYDROLASE (EC 3.2.1.26)
349	350	RXA02026	GR00015	725	6	SUCROSE-6-PHOSPHATE HYDROLASE (EC 3.2.1.26)
351	352	RXA02081	GR00026	1842	349	SUCROSE-6-PHOSPHATE HYDROLASE (EC 3.2.1.26)

Table 1 (continued)

Nucleic Acid	Amino Acid	SEQ ID NO	Contig	NT Start	NT Stop	Function
353	364	RXN01369	W0124	595	1776	MANNOSE-6-PHOSPHATE ISOMERASE (EC 5.3.1.8)
		F RXA01369	GR00398	3	503	MANNOSE-6-PHOSPHATE ISOMERASE (EC 5.3.1.8)
		F RXA01373	GR00399	695	1302	MANNOSE-6-PHOSPHATE ISOMERASE (EC 5.3.1.8)
355	358	RXA02611	GR00743	1	1752	1,4-ALPHA-GLUCAN BRANCHING ENZYME (EC 2.4.1.18)
357	360	RXA02612	GR00743	1793	3985	1,4-ALPHA-GLUCAN BRANCHING ENZYME (EC 2.4.1.18)
359	362	RXN01884	W0184	1	1890	GLYCOGEN DEBRANCHING ENZYME (EC 2.4.1.25) (EC 3.2.1.33)
361	364	F RXA01884	GR00539	3	1475	GLYCOGEN DEBRANCHING ENZYME (EC 2.4.1.25) (EC 3.2.1.33)
363	368	RXA01111	GR00306	16981	17427	GLYCOGEN OPERON PROTEIN GLGX (EC 3.2.1.-)
365	368	RXN01650	W0143	14749	16280	GLYCOGEN PHOSPHORYLASE (EC 2.4.1.1)
367	368	F RXA01550	GR00431	3	1346	GLYCOGEN PHOSPHORYLASE (EC 2.4.1.1)
369	370	RXN02100	W0318	2	2328	GLYCOGEN PHOSPHORYLASE (EC 2.4.1.1)
371	372	F RXA02100	GR00631	3	920	GLYCOGEN PHOSPHORYLASE (EC 2.4.1.1)
373	374	F RXA02113	GR00633	2	1207	GLYCOGEN PHOSPHORYLASE (EC 2.4.1.1)
375	376	RXA02147	GR00639	15516	16532	ALPHA-AMYLASE (EC 3.2.1.1)
377	378	RXA01478	GR00422	10517	12352	GLUCOAMYLASE Q1 AND Q2 PRECURSOR (EC 3.2.1.3)
379	380	RXA01478	GR00539	4388	4923	GLUCOSE-RESISTANCE AMYLASE REGULATOR
381	382	RXA01888	W0127	50623	49244	XYLULOSE KINASE (EC 2.7.1.17)
383	384	RXN01927	GR00555	3	1118	XYLULOSE KINASE (EC 2.7.1.17)
385	386	F RXA01927	GR00762	747	4	RIBOKINASE (EC 2.7.1.15)
387	388	RXA02729	GR00776	1739	2641	RIBOKINASE (EC 2.7.1.15)
389	390	RXA02730	GR00782	1768	731	8-PHOSPHO-BETA-GLUCOSIDASE (EC 3.2.1.86)
391	392	RXA02551	GR00729	2193	2552	DEOXYRIBOSE-PHOSPHATE ALDOLASE (EC 4.1.2.4)
393	394	RXA01325	GR00385	6876	5006	1-deoxy-D-xylulose 5-phosphate reductoisomerase (EC 1.1.1.-)
395	396	RXA00195	GR00030	543	1103	1-deoxy-D-xylulose 5-phosphate reductoisomerase (EC 1.1.1.-)
397	398	RXA00198	GR00030	1094	1708	1-DEOXYXYLULOSE-5-PHOSPHATE SYNTHASE
398	400	RXA01562	W0191	1230	3137	1-DEOXYXYLULOSE-5-PHOSPHATE SYNTHASE
401	402	F RXA01562	GR00436	2	1039	1-DEOXYXYLULOSE-5-PHOSPHATE SYNTHASE
403	404	F RXA01705	GR00480	971	1573	4-ALPHA-GLUCANO- <i>O</i> TRANSFERASE (EC 2.4.1.25)
405	406	RXN00878	W0089	8763	6848	4-ALPHA-GLUCANO- <i>O</i> TRANSFERASE (EC 2.4.1.25), amybromalase
407	408	F RXA00879	GR00242	5827	3828	N-ACETYLGLUCOSAMINE-6-PHOSPHATE DEACETYLASE (EC 3.5.1.25)
409	410	RXN00043	W0119	3244	2081	N-ACETYLGLUCOSAMINYLTRANSFERASE (EC 2.4.1.-)
411	412	F RXA01752	GR00007	3244	2081	N-ACETYLGLUCOSAMINYLTRANSFERASE (EC 2.4.1.-)
413	414	F RXA0043	W0127	35285	33805	N-ACETYLGLUCOSAMINYLTRANSFERASE (EC 2.4.1.-)
415	416	RXN01752	GR00620	1167	610	N-ACETYLGLUCOSAMINYLTRANSFERASE (EC 2.4.1.-)
417	418	F RXA01839	GR00529	1473	547	GLUCOSAMINE-6-PHOSPHATE ISOMERASE (EC 5.3.1.10)
419	420	RXA01859	GR00007	2037	1279	GLUCOSAMINE-6-PHOSPHATE AMINOTRANSFERASE
421	422	RXA0042	GR00422	17271	15397	(ISOMERIZING) (EC 2.6.1.6)
423	424	RXA01482	W0336	2	667	URONATE ISOMERASE (EC 5.3.1.12)
425	426	RXN03179	GR10013	675	4	URONATE ISOMERASE, Glucuronate isomerase (EC 5.3.1.12)
427	428	F RXA02872	W0337	672	163	URONATE ISOMERASE, Glucuronate isomerase (EC 5.3.1.12)
429	430	RXN03180	GR10014	672	163	GALACTOSIDE O-ACETYLTRANSFERASE (EC 2.3.1.16)
431	432	F RXA02873	GR00982	1611	2285	D-RIBITOL-5-PHOSPHATE CYTIDYL TRANSFERASE (EC 2.7.7.40)
433	434	RXA02292	GR00763	7260	6493	D-RIBOSE-BINDING PERPLASMIC PROTEIN PRECURSOR
435	436	RXA02886	GR00032	1216	275	D-RIBOSE-BINDING PERPLASMIC PROTEIN PRECURSOR
437	438	RXA00202	GR00708	5097	4258	
439	440	RXA02440				
	441					

Table 1 (continued)

Nucleic Acid SEQ ID NO	Amino Acid SEQ ID NO	Identification Code Contig	NT Start	NT Stop	Function
443 444	RXN01569	W00098	41086	42444	DTDP-4-DEHYDORHAMNOSE REDUCTASE (EC 1.1.1.133)
445 446	F RXA01569	GR00438	2	427	DTDP-4-DEHYDORHAMNOSE REDUCTASE (EC 1.1.1.133)
447 448	F RXA02056	GR00624	7122	8042	DTDP-4-DEHYDORHAMNOSE REDUCTASE (EC 1.1.1.133)
449 450	RXA00826	GR00222	222	1154	DTDP-GLUCOSE 4,6-DEHYDRATASE (EC 4.2.1.46)
451 452	RXA02054	GR00824	6103	7119	DTDP-GLUCOSE 4,6-DEHYDRATASE (EC 4.2.1.46)
453 454	RXN00427	W01112	7004	8219	DTDP-RHAMNOSE TRANSFERASE RFBF (EC 2.1.1.1)
455 456	F RXA0427	GR00098	1591	2022	DTDP-RHAMNOSE TRANSFERASE RFBF (EC 2.1.1.1)
457 458	RXA00327	GR00067	10263	9890	PROTEIN ARAJ
459 460	RXA00328	GR00057	11147	10858	PROTEIN ARAJ
461 462	RXA00329	GR00057	12390	11187	PROTEIN ARAJ
463 464	RXN01554	W00135	28636	26545	GLUCAN ENDO-1,3-BETA-GLUCOSIDASE A1 PRECURSOR (EC 3.2.1.39)
465 466	RXN02015	W00083	289	8	UDP-GLUCOSE 6-DEHYDROGENASE (EC 1.1.1.22)
467 468	RXN03058	W00028	6258	8936	PUTATIVE HEXULOSE-6-PHOSPHATE ISOMERASE (EC 5.3.1.1)
469	RXN03030	W00098	57008	58443	PERIPLASMIC BETA-GLUCOSIDASE/BETA-XYLOSIDASE PRECURSOR (EC 3.2.1.21) (EC 3.2.1.37)
471 472	RXN00401	W00025	12427	11489	5-DEHYDRO-4-DEOXYGLUCARATE DEHYDRATASE (EC 4.2.1.41)
473	RXN02125	W0102	23242	22442	ALDOSE REDUCTASE (EC 1.1.1.21)
475 476	RXN00290	W01B1	1679	5116	Arabinosyltransferase subunit B (EC 2.4.2.1)
477	RXN01175	W0017	39888	38303	PHOSPHO-2-DEHYDRO-3-DEOXYHEPTONATE ALDOLASE (EC 4.1.2.15)
479	RXN01376	W0091	5810	4750	PUTATIVE GLYCOSYL TRANSFERASE WBF
481	RXN01631	W0050	47021	48143	PUTATIVE HEXULOSE-6-PHOSPHATE ISOMERASE (EC 5.3.1.1)
483	RXN01593	W0229	13274	12408	NAGD PROTEIN
485	RXN00337	W0197	20369	21418	GALACTOKINASE (EC 2.7.1.6)
487	RXN00584	W0323	5518	8840	PHOSPHO-2-DEHYDRO-3-DEOXYHEPTONATE ALDOLASE (EC 4.1.2.15)
489	RXN02574				PHOSPHO-2-DEHYDRO-3-DEOXYHEPTONATE ALDOLASE (EC 4.1.2.15)
491	RXN03216				PHOSPHO-2-DEHYDRO-3-DEOXYHEPTONATE ALDOLASE (EC 4.1.2.15)
493	F RXA01916	GR00549	1	1008	GLUCOSE-FRUCTOSE OXIDOREDUCTASE PRECURSOR (EC 1.1.9.28)
					1.1.9.28)
495	RXN03224	GR00008	1417	260	CYCLOMALTODEXTRINASE (EC 3.2.1.54)
497	F RXA00038	RXC00233			CYCLOMALTODEXTRINASE (EC 3.2.1.54)
499		RXC00238			Protein involved in sugar metabolism
501		RXC00271			Membrane Lipoprotein involved in sugar metabolism
503		RXC00338			Cytosolic Protein involved in sugar metabolism
505		RXC00362			Exported Protein involved in sugar metabolism
507		RXC00412			Membrane Spanning Protein involved in metabolism of disaccharides
509					Amino Acid ABC Transporter ATP-Binding Protein involved in sugar metabolism
511		RXC00528			ABC Transporter ATP-Binding Protein involved in sugar metabolism
513		RXC01004			Membrane Spanning Protein involved in sugar metabolism
515		RXC01017			Cytosolic Protein involved in sugar metabolism
517		RXC01021			Cytosolic Kinase involved in metabolism of sugars and thiamin
519		RXC01212			ABC Transporter ATP-Binding Protein involved in sugar metabolism
521		RXC01308			Membrane Spanning Protein involved in sugar metabolism
523		RXC01386			Cytosolic Protein involved in sugar metabolism
		RXC01372		526	Cytosolic Protein involved in sugar metabolism

Table 1 (continued)

Nucleic Acid	Amino Acid	Identification Code	Contig.	NT Start	NT Stop	Function
	<u>SEQ ID NO</u>					
527	526	RXC01859				protein involved in sugar metabolism
529	530	RXC01663				protein involved in sugar metabolism
531	532	RXC01693				protein involved in sugar metabolism
533	534	RXC01703				Cytosolic Protein involved in sugar metabolism
535	536	RXC02254				Membrane Associated Protein involved in sugar metabolism
537	538	RXC02255				Cytosolic Protein involved in sugar metabolism
539	540	RXC02435				protein involved in sugar metabolism
541	542	F RXA02435		GR00709	825	268
543	544	RXC03216				Uncharacterized protein involved in glycerol metabolism (homolog of <i>Drosophila rhomboid</i>)
						protein involved in sugar metabolism
TCA-cycle						
Nucleic Acid	Amino Acid	Identification Code	Contig.	NT Start	NT Stop	Function
	<u>SEQ ID NO</u>					
545	546	RXA02175		GR00641	10710	9418
547	548	RXA02621		GR00746	2847	1829
549	550	RXN00519		W0144	5585	3372
551	552	F RXA00521		GR00133	2	1080
553	554	RXN02209		W0304	1	1671
555	556	F RXA02209		GR00848	3	1661
557	558	RXN02213		W0305	1378	2151
559	560	F RXA02213		GR00648	1330	2046
561	562	RXA02058		GR00825	3	2870
563	564	RXA01745		GR00495	2	1495
						2-OXOGLUTARATE DEHYDROGENASE COMPLEX (EC 2.3.1.61)
565	566	RXA00782		GR00206	3984	3103
567	568	RXA00783		GR00206	5280	4009
569	570	RXN01695		W0139	11307	12808
571	572	F RXA01616		GR00449	8808	9546
573	574	F RXA01695		GR00474	4398	4178
575	576	RXA00290		GR00046	4893	5855
577	578	RXN01048		W0079	12539	11316
579	580	F RXA01048		GR00298	3	280
581	582	F RXA00290		GR00046	4883	5856
583	584	RXN03101		W0086	2	583
						L-MALATE DEHYDROGENASE (ACCEPTOR) (EC 1.1.99.16)
585	586	POIN02048		W0025	15058	14840
587	588	RXN00389		W0025	11481	9922
						SUCCINYLCOA SYNTHETASE ALPHA CHAIN (EC 6.2.1.5)
						SUCCINYLCOA SYNTHETASE BETA CHAIN (EC 6.2.1.5)
						L-MALATE DEHYDROGENASE (ACCEPTOR) (EC 1.1.99.16)
						L-MALATE DEHYDROGENASE (ACCEPTOR) (EC 1.1.99.16)
						MALIC ENZYME (EC 1.1.1.39)
						MALIC ENZYME (EC 1.1.1.39)
						DHYDROGLUTAMIDE SUCCINYLTRANSFERASE COMPLEX (EC 2.3.1.61)
						2-OXOGLUTARATE DEHYDROGENASE COMPLEX (EC 2.3.1.61)
						DIHYDROGLUTAMIDE SUCCINYLTRANSFERASE COMPLEX (EC 2.3.1.61)
						OXOGLUTARATE DEHYDROGENASE COMPLEX (EC 2.3.1.61)
						oxoglutarate semialdehyde dehydrogenase (EC 1.2.1.-)

Table 1 (continued)

Glyoxylate bypass		
<u>Nucleic Acid Seq ID No</u>	<u>Amino Acid Seq ID No</u>	<u>Identification Code</u>
<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
589	590	RXN02399
		F RXA02399
591	592	RXN02404
		F RXA02404
593	594	RXAO1089
595	596	RXAO11089
597	598	RXAO1888
599	600	

Methylcitrate-pathway

<u>Nucleic Acid Seq ID No</u>	<u>Amino Acid Seq ID No</u>	<u>Identification Code</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
600	602	RXN03117	VV0092	3087	1576
		F RXA00406	GR00090	978	4
		F RXA00514	GR00130	1883	1576
603	604	RXA00512	GR00130	621	4
		RXA00518	GR00131	3069	2773
607	610	RXA01077	GR00300	4847	8017
		RXN03144	VV0141	2	2-methylisocitrate synthase (EC 5.3.3.-)
609	612	F RXA02322	GR00888	416	5
		ROA02328	GR00889	807	2-methylisocitrate synthase (EC 5.3.3.-)
611	614	ROA02332	GR00871	1908	784
		RXN02333	VV0141	901	2-methylisocitrate synthase (EC 4.1.3.31)
613	616	F RXA02333	GR00871	2120	methylisocitrate lyase (EC 4.1.3.30)
		ROA00050	GR00003	9590	methylisocitrate lyase (EC 4.1.3.30)
615	618				LACTOYLGLUTATHIONE LYASE (EC 4.4.1.5)
617	620				
619	622				
621	624				
623	626				

Methyl-Malonyl-CoA-Mutases

<u>Nucleic Acid Seq ID No</u>	<u>Amino Acid Seq ID No</u>	<u>Identification Code</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
626	628	RXN00148	VV0167	9849	METHYLMALONYL-COA MUTASE ALPHA-SUBUNIT (EC 5.4.99.2)
627	630	F RXA00148	GR00023	2002	METHYLMALONYL-COA MUTASE ALPHA-SUBUNIT (EC 5.4.99.2)
	632	ROA00149	GR00023	3858	METHYLMALONYL-COA MUTASE BETA-SUBUNIT (EC 5.4.99.2)

Table 1 (continued)

Others		Amino Acid		Identification Code		Contig.		NT Start	NT Stop	Function
Nucleic Acid	SEQ ID NO	SEQ ID NO	SEQ ID NO	SEQ ID NO	SEQ ID NO	SEQ ID NO	Contig.			
631	634	RXN00317	W0197	28879	27532	PHOSPHOGLYCOLATE PHOSPHATASE (EC 3.1.3.18)				
635	636	F RXA00317	GR00055	344	6	PHOSPHOGLYCOLATE PHOSPHATASE (EC 3.1.3.18)				
637	638	RXA02198	GR00845	3856	3284	PHOSPHOGLYCOLATE PHOSPHATASE (EC 3.1.3.18)				
639	640	RXN02461	W0124	14236	14843	PHOSPHOGLYCOLATE PHOSPHATASE (EC 3.1.3.18)				
Redox Chain										
Nucleic Acid	Amho Acid	Identification Code	Contig.	NT Start	NT Stop	Function				
641	642	RXN01744	W0174	2350	812	CYTOCHROME D UBIQUINOL OXIDASE SUBUNIT I (EC 1.10.3.-)				
643	644	F RXA00055	GR00008	11753	11880	CYTOCHROME D UBIQUINOL OXIDASE SUBUNIT I (EC 1.10.3.-)				
645	646	F RXA01744	GR00494	2113	812	CYTOCHROME D UBIQUINOL OXIDASE SUBUNIT I (EC 1.10.3.-)				
647	648	RXA00378	GR00082	212	6	CYTOCHROME C-TYPE BIOGENESIS PROTEIN CCDA				
649	650	RXA00385	GR00083	773	435	CYTOCHROME C-TYPE BIOGENESIS PROTEIN CCDA				
651	652	RXA01743	GR00494	806	6	CYTOCHROME D UBIQUINOL OXIDASE SUBUNIT II (EC 1.10.3.-)				
653	654	RXN02480	W0084	31222	28567	CYTOCHROME C OXIDASE POLYPEPTIDE I (EC 1.9.3.1)				
655	656	F RXA01919	GR00550	288	4	CYTOCHROME C OXIDASE POLYPEPTIDE I (EC 1.9.3.1)				
657	658	F RXA02480	GR00717	1449	601	CYTOCHROME C OXIDASE POLYPEPTIDE I (EC 1.9.3.1)				
659	660	F RXA02481	GR00717	1945	1334	CYTOCHROME C OXIDASE POLYPEPTIDE I (EC 1.9.3.1)				
661	662	RXA02140	GR00839	7339	8415	CYTOCHROME C OXIDASE POLYPEPTIDE II (EC 1.9.3.1)				
663	664	RXA02142	GR00639	9413	10083	CYTOCHROME C OXIDASE POLYPEPTIDE I (EC 1.9.3.1)				
665	666	RXA02144	GR00639	11026	12248	RIESKE IRON-SULFUR PROTEIN				
667	668	RXA02740	GR00763	7813	6542	PROBABLE CYTOCHROME C OXIDASE ASSEMBLY FACTOR				
669	670	RXA02743	GR00763	13534	12497	CYTOCHROME AA3 CONTROLLING PROTEIN				
671	672	RXA01227	GR00355	1199	1519	FERREDOXIN				
673	674	RXA01885	GR00532	438	122	FERREDOXIN VI				
675	676	RXA00680	GR00179	2632	2315	FERREDOXIN-NAD(+) REDUCTASE (EC 1.16.1.3)				
677	678	RXA00679	GR00179	2302	1037	FERREDOXIN-TRANSFER FLAVOPROTEIN ALPHA-SUBUNIT				
679	680	RXA00224	GR00032	24985	24015	ELECTRON TRANSFER FLAVOPROTEIN BETA-SUBUNIT				
681	682	RXA00225	GR00032	25783	24988	NADH DEHYDROGENASE I CHAIN L (EC 1.6.5.3)				
683	684	RXN00608	VV0192	11289	9026	NADH DEHYDROGENASE I CHAIN L (EC 1.6.5.3)				
685	686	F RXA00808	GR00160	121	1869	NADH DEHYDROGENASE I CHAIN M (EC 1.6.5.3)				
687	688	RXN00695	VV0192	8842	7113	NADH DEHYDROGENASE I CHAIN M (EC 1.6.5.3)				
689	690	F RXA00608	GR00160	2253	3017	NADH DEHYDROGENASE I CHAIN M (EC 1.6.5.3)				
691	692	RXA00913	GR00249	3	2120	NADH DEHYDROGENASE I CHAIN L (EC 1.6.5.3)				
693	694	RXA00908	GR00247	2552	3406	NADH DEHYDROGENASE I CHAIN L (EC 1.6.5.3)				
695	696	RXA00700	GR00182	846	43	NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 2				
697	698	RXN00463	VV0098	44924	46287	NADH-UBIQUINONE OXIDOREDUCTASE 39 KD SUBUNIT PRECURSOR (EC 1.6.5.3) (EC 1.6.9.3)				

Table 1 (continued)

<u>Nucleic Acid Seq ID No</u>	<u>Amino Acid Seq ID No</u>	<u>Identification Code</u>	<u>Contig</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
699	700	F RXA00483	GR00119	19108	20569	NADH-UBIQUINONE OXIDOREDUCTASE 39 KD SUBUNIT PRECURSOR (EC 1.6.5.3) (EC 1.6.99.3)
701	702	RXA01534	GR00427	1036	547	NADH-DEPENDENT FMN OXIDOREDUCTASE
703	704	RXA00288	GR00046	2646	1636	QUINONE OXIDOREDUCTASE (EC 1.6.5.5)
705	706	RXA02741	GR00763	9585	8620	QUINONE OXIDOREDUCTASE (EC 1.6.5.5)
707	708	RXN02580	W0101	9822	10788	NADPH-FLAVIN OXIDOREDUCTASE (EC 1.6.88.-)
709	710	F RXA02580	GR00731	6339	7180	NADPH-FLAVIN OXIDOREDUCTASE (EC 1.6.99.-)
711	712	RXA01311	GR00380	1611	865	SUCCINATE DEHYDROGENASE IRON-SULFUR PROTEIN (EC 1.3.99.1)
713	714	RXN03014	W0058	1273	368	NADH DEHYDROGENASE I CHAIN M (EC 1.6.5.3)
715	716	F RXA00910	GR00248	3	1258	Hydrogenase subunits
717	718	RXN01895	W0117	865	5	NADH DEHYDROGENASE (EC 1.6.99.3)
719	720	F RXA01895	GR00543	2	817	DEHYDROGENASE
721	722	RXA00703	GR00183	2558	271	FORMATE DEHYDROGENASE ALPHA CHAIN (EC 1.2.1.2)
723	724	RXN00705	W0005	8111	5197	FDHD PROTEIN
725	726	F RXA00705	GR00184	1291	407	FDHD PROTEIN
727	728	RXN00388	W0025	2081	3081	CYTOCHROME C BIOGENESIS PROTEIN CCSA
729	730	F RXA00388	GR00085	969	687	essential protein similar to cytochrome c
731	732	F RXA00388	GR00084	514	6	RESC PROTEIN, essential protein similar to cytochrome c biogenesis protein
733	734	RXA00845	GR00259	1876	2847	putative cytochrome oxidase
735	736	RXN02558	W0101	8602	6759	FLAVOHEMOPROTEIN / DIHYDROPTEROINE REDUCTASE (EC 1.6.99.7)
737	738	F RXA02558	GR00731	2019	3176	FLAVOHEMOPROTEIN
739	740	RXA01392	GR00408	2297	3373	GLUTATHIONE S-TRANSFERASE (EC 2.5.1.18)
741	742	RXA00800	GR00214	2031	3134	GLUTATHIONE-DEPENDENT FORMALDEHYDE DEHYDROGENASE (EC 1.2.1.1)
743	744	RXA02143	GR00639	10138	11025	QCRC PROTEIN, menaquinol:cytochrome c oxidoreductase
745	746	RXN03098	W0058	405	4	NADH DEHYDROGENASE I CHAIN M (EC 1.6.6.3)
747	748	RXN02038	W0176	32683	33083	NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 4 (EC 1.6.5.3)
749	750	RXN02765	W0317	3552	2794	Hypothetical Oxidoreductase
751	752	RXN02208	W0302	1784	849	Hypothetical Oxidoreductase
753	754	RXN02554	W0101	4633	4010	Hypothetical Oxidoreductase (EC 1.1.1.-)

ATP-Synthase

<u>Nucleic Acid Seq ID No</u>	<u>Amino Acid Seq ID No</u>	<u>Identification Code</u>	<u>Contig</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
755	756	RXN01204	W0121	1270	461	ATP SYNTHASE A CHAIN (EC 3.6.1.34)
757	758	F RXA01204	GR00345	394	1155	ATP SYNTHASE A CHAIN (EC 3.6.1.34)
759	760	RXA01201	GR00344	675	2316	ATP SYNTHASE ALPHA CHAIN (EC 3.6.1.34)
761	762	RXN01193	W0175	5280	3832	ATP SYNTHASE BETA CHAIN (EC 3.6.1.34)
763	764	F RXA01193	GR00343	15	795	ATP SYNTHASE BETA CHAIN (EC 3.6.1.34)
	765	F RXA01203	GR00344	3365	3993	ATP SYNTHASE BETA CHAIN (EC 3.6.1.34)

Table 1 (continued)

<u>Nucleic Acid</u>	<u>Amino Acid</u>	<u>Identification Code</u>	<u>Contd.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
<u>SEQ ID NO</u>	<u>SEQ ID NO</u>					
767	768	RXN02821	W0121	324	85	ATP SYNTHASE C CHAIN (EC 3.6.1.34)
769	770	FRXA02821	GR00802	139	318	ATP SYNTHASE C CHAIN (EC 3.6.1.34)
771	772	RXA01200	GR00344	2	610	ATP SYNTHASE DELTA CHAIN (EC 3.6.1.34)
773	774	RXA01194	GR00343	770	1141	ATP SYNTHASE EPSILON CHAIN (EC 3.6.1.34)
775	776	RXA01202	GR00344	2376	3249	ATP SYNTHASE GAMMA CHAIN (EC 3.6.1.34)
777	778	RXN02434	V0080	4923	3274	ATP-BINDING PROTEIN

Cytochrome metabolism

<u>Nucleic Acid</u>	<u>Amino Acid</u>	<u>Identification Code</u>	<u>Contd.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
<u>SEQ ID NO</u>	<u>SEQ ID NO</u>					
779	780	RXN0084	W0005	29884	28581	CYTOCHROME P450 11B (EC 1.14.1.1)
781	782	RXN00387	W0025	1150	2004	Hypothetical Cytochrome c Biogenesis Protein

TABLE 2 - Excluded Genes

GenBank™ Accession No.	Gene Name	Gene Function	Reference
A09073	ppg	Phosphoenol pyruvate carboxylase	Bachmann, B. et al. "DNA fragment coding for phosphoenolpyruvat carboxylase, recombinant DNA carrying said fragment, strains carrying the recombinant DNA and method for producing L-aminino acids using said strains," Patent: EP 0358940-A 3 03/21/90
A45579, A45581, A45583, A45585 A45587		Threonine dehydratase	Moeckel, B. et al. "Production of L-isoleucine by means of recombinant micro-organisms with deregulated threonine dehydratase," Patent: WO 9519442-A 5 07/20/95
AB003132	murC; ftsQ; ftsZ		Kobayashi, M. et al. "Cloning, sequencing, and characterization of the ftsZ gene from coryneform bacteria," <i>Biochim. Biophys. Res. Commun.</i> , 236(2):383-388 (1997)
AB015023	murC; ftsQ		Wachi, M. et al. "A murC gene from Coryneform bacteria," <i>Appl. Microbiol. Biotechnol.</i> , 51(2):223-228 (1999)
AB018530	disR		Kimura, E. et al. "Molecular cloning of a novel gene, disR, which rescues the detergent sensitivity of a mutant derived from <i>Brevibacterium lactofermentum</i> ," <i>Biochi. Biotechnol. Biochem.</i> , 60(10):1565-1570 (1996)
AB018531	disR1; disR2	D-glutamate racemase	
AB020624	murI	transketolase	
AB023377	txt	Glutamine 2-oxoglutamate aminotransferase large and small subunits	
AB024708	gltB; gltD	aconitase	
AB025424	acn	Replication protein	
AB027714	rep; aad	adenyltransferase	
AF005242	argC	N-acetylglutamate- γ -semialdehyde dehydrogenase	
AF005635	glnA	Glutamine synthetase	
AF030405	hisF	cyclase	
AF030520	argG	Argininosuccinate synthetase	
AF031518	argF	Ornithine carbamoyltransferase	
AF036932	aroD	3-dehydroquinate dehydratase	
AF038548	pyc	Pyruvate carboxylase	

Table 2 (continued)

AF038651	dciAE; apt; rel	Dipeptide-binding protein; adenine phosphoribosyltransferase; GTP pyrophosphokinase	Wehmeyer, L. et al. "The role of the <i>Corynebacterium glutamicum</i> rel gene in (p)ppGpp metabolism," <i>Microbiology</i> , 144:1853-1862 (1998)
AF041436	argR	Arginine repressor	
AF045998	impA	Inositol monophosphate phosphatase	
AF048764	argH	Argininosuccinate lyase	
AF049897	argC; argJ; argB; argD; argF; argR; argG; argH	N-acetylglutamylphosphate reductase; ornithine acetyltransferase; N-acetylglutamate kinase; acetylornithine transminase; ornithine carbamoyltransferase; arginine repressor; argininosuccinate synthase; argininosuccinate lyase	
AF050109	inhA	Enoyl-acyl carrier protein reductase	
AF050166	hisG	ATP phosphoribosyltransferase	
AF051846	hisA	Phosphoribosylformimino-5-amino-1-phosphoribosyl-4-imidazolecarboxamide isomerase	
AF052652	metA	Homoserine O-acetyltransferase	Park, S. et al. "Isolation and analysis of metA, a methionine biosynthetic gene encoding homoserine acetyltransferase in <i>Corynebacterium glutamicum</i> ," <i> Mol. Cells.</i> , 8(3):286-294 (1998)
AF053071	aroB	Dehydroquinate synthetase	
AF060558	hisH	Glutamine amidotransferase	
AF086704	hisE	Phosphoribosyl-ATP-pyrophosphohydrolyase	
AF114233	aroA	S-enolpyruvylshikimate 3-phosphate synthase	
AF116184	pamD	L-aspartate-alpha-decarboxylase precursor	Dusch, N. et al. "Expression of the <i>Corynebacterium glutamicum</i> pamD gene encoding L-aspartate-alpha-decarboxylase leads to pantothenate overproduction in <i>Escherichia coli</i> ," <i>Appl. Environ. Microbiol.</i> , 65(4):1530-1539 (1999)
AF124518	aroD; aroE	3-dehydroquinate; shikimate dehydrogenase	
AF124600	aroC; aroK; aroB; pepQ	Chorismate synthase; shikimate kinase; 3-dehydroquinate synthase; putative cytoplasmic peptidase	
AF145897	inhA		
AF145898	inhA		

Table 2 (continued)

Table 2 (continued)			
AJ001436	ectP	Transport of ectoine, glycine betaine, proline	Peter, H. et al. "Corynebacterium glutamicum is equipped with four secondary carriers for compatible solutes: Identification, sequencing, and characterization of the proline/ectoine uptake system, ProP, and the ectoine/proline/glycine betaine carrier, EctP," <i>J. Bacteriol.</i> , 180(22):6005-6012 (1998)
AJ004934	dapD	Tetrahydrodipicolinate succinylase (incomplete)	Wehrmann, A. et al. "Different modes of diaminopimelate synthesis and their role in cell wall integrity: A study with <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 180(12):3159-3165 (1998)
AJ007732	ppc; secG; amt; ocd; soxA	Phosphoenolpyruvate-carboxylase; ?; high affinity ammonium uptake protein; putative ornithine-cyclodecarboxylase; sarcosine oxidase	Jakoby, M. et al. "Nitrogen regulation in <i>Corynebacterium glutamicum</i> : Isolation of genes involved in biochemical characterization of corresponding proteins," <i>FEMS Microbiol.</i> , 173(2):303-310 (1999)
AJ010319	ftsY, glnB, glnD; sfp; amtP	Involved in cell division; PII protein; uridylyltransferase (uridyl)-removing enzyme; signal recognition particle; low affinity ammonium uptake protein	Molenaar, D. et al. "Biochemical and genetic characterization of the membrane-associated malate dehydrogenase (acceptor) from <i>Corynebacterium glutamicum</i> ," <i>Eur. J. Biochem.</i> , 254(2):395-403 (1998)
AJ132968	cat	Chloramphenicol acetyl transferase	L-malate: quinone oxidoreductase
AJ224946	mqo		
AJ238250	ndh	NADH dehydrogenase	Lichtinger, T. et al. "Biochemical and biophysical characterization of the cell wall porin of <i>Corynebacterium glutamicum</i> : The channel is formed by a low molecular mass polypeptide," <i>Biochemistry</i> , 37(43):15024-15032 (1998)
AJ238703	porA	Porin	Vertes et al. "Isolation and characterization of IS31831, a transposable element from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 11(4):739-746 (1994)
D17429		Transposable element IS31831	Usuda, Y. et al. "Molecular cloning of the <i>Corynebacterium glutamicum</i> (Brevibacterium lactofermentum AJ12036) odhA gene encoding a novel type of 2-oxoglutarate dehydrogenase," <i>Microbiology</i> , 142:3347-3354 (1996)
D84102	odhA	2-oxoglutarate dehydrogenase	Katsunuma, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 1 10/12/87
E011358	hdh; hik	Homoserine dehydrogenase; homoserine kinase	Katsunuma, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 2 10/12/87
E013359		Upstream of the start codon of homoserine kinase gene	
E01375		Tryptophan operon	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87
E01376	trpL; trpE	Leader peptide; anthranilate synthase	

Table 2 (continued)

E01377	Promoter and operator regions of tryptophan operon	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87
E03937	Biotin-synthase	Hatakeyama, K. et al. "DNA fragment containing gene capable of coding biotin synthetase and its utilization," Patent: JP 1992278088-A 1 10/02/92
E04040	Diamino pelargonic acid aminotransferase	Kohama, K. et al. "Gene coding diamino pelargonic acid aminotransferase and deshiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04041	Deshiobiotinsynthetase	Kohama, K. et al. "Gene coding diamino pelargonic acid aminotransferase and deshiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04307	Flavum aspartase	Kurusu, Y. et al. "Gene DNA coding aspartase and utilization thereof," Patent: JP 1993030977-A 1 02/09/93
E04376	Isocitric acid lyase	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
E04377	Isocitric acid lyase N-terminal fragment	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
E04484	Prephenate dehydratase	Sotouchi, N. et al. "Production of L-phenylalanine by fermentation," Patent: JP 1993076352-A 2 03/10/93
E05108	Aspartokinase	Fuguno, N. et al. "Gene DNA coding Aspartokinase and its use," Patent: JP 1993184366-A 1 07/27/93
E05112	Dihydro-dipicolinic acid synthetase	Hatakeyama, K. et al. "Gene DNA coding dihydroadipicolinic acid synthetase and its use," Patent: JP 1993184371-A 1 07/27/93
E05776	Diaminopimelic acid dehydrogenase	Kobayashi, M. et al. "Gene DNA coding Diaminopimelic acid dehydrogenase and its use," Patent: JP 1993284970-A 1 11/02/93
E05779	Threonine synthase	Kohama, K. et al. "Gene DNA coding threonine synthase and its use," Patent: JP 1993284972-A 1 11/02/93
E06110	Prephenate dehydratase	Kikuchi, T. et al. "Production of L-phenylalanine by fermentation method," Patent: JP 1993344881-A 1 12/27/93
E06111	Mutated Prephenate dehydratase	Kikuchi, T. et al. "Production of L-phenylalanine by fermentation method," Patent: JP 1993344881-A 1 12/27/93
E06146	Acetohydroxy acid synthetase	Inui, M. et al. "Gene capable of coding Acetohydroxy acid synthetase and its use," Patent: JP 1993344893-A 1 12/27/93
E06825	Aspartokinase	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E06826	Mutated aspartokinase alpha subunit	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94

Table 2 (continued)

E06827		Mutated aspartokinase alpha subunit	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E07701	secY		Honno, N. et al. "Gene DNA participating in integration of membranous protein to membrane," Patent: JP 1994169780-A 1 06/21/94
E08177		Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A 1 09/20/94
E08178, E08179, E08180, E08181, E08182		Feedback inhibition-released Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A 1 09/20/94
E08232		Acetohydroxy-acid isomerase	Inui, M. et al. "Gene DNA coding acetohydroxy acid isomerase," Patent: JP 1994277067-A 1 10/04/94
E08234	secE		Asai, Y. et al. "Gene DNA coding for translocation machinery of protein," Patent: JP 1994277073-A 1 10/04/94
E08643		FT aminotransferase and deathiotobiotin synthetase promoter region	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A 1 02/03/95
E08646		Biotin synthetase	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A 1 02/03/95
E08649		Aspartase	Kohama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031478-A 1 02/03/95
E08900		Dihydrodipicolinate reductase	Madori, M. et al. "DNA fragment containing gene coding Dihydrodipicolinate acid reductase and utilization thereof," Patent: JP 1995075578-A 1 03/20/95
E08901		Diaminopimelic acid decarboxylase	Madori, M. et al. "DNA fragment containing gene coding Diaminopimelic acid decarboxylase and utilization thereof," Patent: JP 1995075579-A 1 03/20/95
E12594		Serine hydroxymethyltransferase	Hatakeyama, K. et al. "Production of L-tryptophan," Patent: JP 1997028391-A 1 02/04/97
E12760, E12759, E12758		transposase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12764		Arginy-tRNA synthetase; diaminopimelic acid decarboxylase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12767		Dihydrodipicolinic acid synthetase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12770		aspartokinase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12773		Dihydrodipicolinic acid reductase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97

Table 2 (continued)

E13655		Glucose-6-phosphate dehydrogenase	Hatakeyama, K. et al. "Glucose-6-phosphate dehydrogenase and DNA capable of coding the same," Patent: JP 1997224661-A 1 09/02/97
L01508	IlvA	Threonine dehydratase	Moeckel, B. et al. "Functional and structural analysis of the threonine dehydratase of <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 174:8065-8072 (1992)
L07603	EC 4.2.1.15	3-deoxy-D-arabinoheptulosonate-7-phosphate synthase	Chen, C. et al. "The cloning and nucleotide sequence of <i>Corynebacterium glutamicum</i> 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase gene," <i>FEMS Microbiol. Lett.</i> , 107:223-230 (1993)
L09232	IlvB; ilvN; ilvC	Acetohydroxy acid synthase large subunit; Acetohydroxy acid synthase small subunit; Acetohydroxy acid isomero-reductase	Keilhauer, C. et al. "Isoleucine synthesis in <i>Corynebacterium glutamicum</i> : molecular analysis of the ilvB-ilvN-ilvC operon," <i>J. Bacteriol.</i> , 175(17):5595-5603 (1993)
L18874	PtsM	Phosphoenolpyruvate sugar phosphotransferase	Fouet, A et al. "Bacillus subtilis sucrose-specific enzyme II of the phosphotransferase system: expression in <i>Escherichia coli</i> and homology to enzymes II from enteric bacteria," <i>PNAS USA</i> , 84(24):8773-8777 (1987); Lee, J.K. et al. "Nucleotide sequence of the gene encoding the <i>Corynebacterium glutamicum</i> mannose enzyme II and analyses of the deduced protein sequence," <i>FEMS Microbiol. Lett.</i> , 119(1-2):137-145 (1994)
L27123	aceB	Malate synthase	Lee, H.-S. et al. "Molecular characterization of aceB, a gene encoding malate synthase in <i>Corynebacterium glutamicum</i> ," <i>J. Microbiol. Biotechnol.</i> , 4(4):256-263 (1994)
L27126		Pyruvate kinase	Jetten, M. S. et al. "Structural and functional analysis of pyruvate kinase from <i>Corynebacterium glutamicum</i> ," <i>Appl. Environ. Microbiol.</i> , 60(7):2501-2507 (1994)
L28760	aceA	Isocitrate lyase	Oguiza, J.A. et al. "Molecular cloning, DNA sequence analysis, and characterization of the <i>Corynebacterium diphtheriae</i> dtxR from <i>Brevibacterium lactofermentum</i> ," <i>J. Bacteriol.</i> , 177(2):465-467 (1995)
L33906	dtx	Diphtheria toxin repressor	Follette, M.T. et al. "Molecular cloning and nucleotide sequence of the <i>Corynebacterium glutamicum</i> pheA gene," <i>J. Bacteriol.</i> , 167:695-702 (1986)
M13774		Prephenate dehydratase	Park, Y.-H. et al. "Phylogenetic analysis of the coryneform bacteria by 5S rRNA sequences," <i>J. Bacteriol.</i> , 169:1801-1806 (1987)
M16173	5S rRNA		Sano, K. et al. "Structure and function of the trp operon control regions of <i>Brevibacterium lactofermentum</i> , a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
M16663	trpE	Anthranilate synthase, 5' end	Sano, K. et al. "Structure and function of the trp operon control regions of <i>Brevibacterium lactofermentum</i> , a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
M16664	trpA	Tryptophan synthase, 3' end	

Table 2 (continued)

M23819	Phosphoenolpyruvate carboxylase	O'Regan, M. et al. "Cloning and nucleotide sequence of the Phosphoenolpyruvate carboxylase-coding gene of <i>Corynebacterium glutamicum</i> ATCC13032," <i>Gene</i> , 77(2):237-251 (1989)
M85106	23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)
M85107, M85108	23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)
M89931	accD; bmrQ; yhbw	Beta C-S lyase; branched-chain amino acid uptake carrier; hypothetical protein yhbw
S59299	trp	Leader gene (promoter)
U11345	trpD	Antennalate phosphoribosyltransferase
U13922	cglIM; cglIR; cglIR	Putative type II 5-cyanoine methyltransferase; putative type II restriction endonuclease; putative type I or type III restriction endonuclease
U14965	recA	
U31224	ppx	
U31225	proc	L-proline: NADP+ 5-oxidoreductase
U31230	obj; proB; unkdh	7-gamma glutamyl kinase; similar to D-isomer specific 2-hydroxyacid dehydrogenases

Table 2 (continued)

U31281	bioB	Biotin synthase	Serebrykii, I.G., "Two new members of the bio B superfamily: Cloning, sequencing and expression of bio B genes of <i>Methylobacillus flagellatum</i> and <i>Corynebacterium glutamicum</i> ," <i>Gene</i> , 175:15-22 (1996)
U35023	thrR; accBC	Thiosulfate sulfurtransferase; acyl CoA carboxylase	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene encoding a two-domain protein similar to biotin carboxylases and biotin-carboxyl-carrier proteins," <i>Arch. Microbiol.</i> , 166(2):76-82 (1996)
U43535	cmr	Multidrug resistance protein	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene conferring multidrug resistance in the heterologous host <i>Escherichia coli</i> ," <i>J. Bacteriol.</i> , 179(7):2449-2451 (1997)
U43536	cjbB	Heat shock ATP-binding protein	
U53587	3'5"-aminoglycoside phosphotransferase		
U89648		<i>Corynebacterium glutamicum</i> unidentified sequence involved in histidine biosynthesis, partial sequence	Matsui, K. et al. "Complete nucleotide and deduced amino acid sequences of the <i>Brevibacterium lactofermentum</i> tryptophan operon," <i>Nucleic Acids Res.</i> , 14(24):10113-10114 (1986)
X04960	tppA; tppB; tppC; tppD; tppE; tppG; tppL	DAP decarboxylase (meso-diaminopimelate decarboxylase, EC 4.1.1.20)	Yeh, P. et al. "Nucleic sequence of the <i>lysA</i> gene of <i>Corynebacterium glutamicum</i> and possible mechanisms for modulation of its expression," <i>Mol. Gen. Genet.</i> , 212(1):112-119 (1988)
X07563	lys A	Tryptophan operon	Eikmanns, B.J. et al. "The Phosphoenolpyruvate carboxylase gene of <i>Corynebacterium glutamicum</i> : Molecular cloning, nucleotide sequence, and expression," <i>Mol. Gen. Genet.</i> , 218(2):330-339 (1989); Lepiniec, L. et al. "Sorghum Phosphoenolpyruvate carboxylase gene family: structure, function and molecular evolution," <i>Plant. Mol. Biol.</i> , 21 (3):487-502 (1993)
X14234	EC 4.1.1.31	Phosphoenolpyruvate carboxylase	Von der Osten, C.H. et al. "Molecular cloning, nucleotide sequence and fine-structural analysis of the <i>Corynebacterium glutamicum fda</i> gene: structural comparison of <i>C. glutamicum</i> fructose-1, 6-biphosphate aldolase to class I and class II aldolases," <i>Mol. Microbiol.</i>
X17313	fda	Fructose-bisphosphate aldolase	Bonnassie, S. et al. "Nucleic sequence of the <i>dapA</i> gene from <i>Corynebacterium glutamicum</i> ," <i>Nucleic Acids Res.</i> , 18(21):6421 (1990)
X33993	dapA	L-2, 3-dihydrodipicolinate synthetase (EC 4.2.1.52)	Cianciotto, N. et al. "DNA sequence homology between att B-related sites of <i>Corynebacterium diphtheriae</i> , <i>Corynebacterium ulcerans</i> , <i>Corynebacterium glutamicum</i> , and the attP site of <i>lambda</i> corynephage," <i>FEMS Microbiol. Lett.</i> , 66:299-302 (1990)
X34223		AttB-related site	
X34740	args; lysA	Arginyl-tRNA synthetase; Diaminopimelate decarboxylase	Marcel, T. et al. "Nucleotide sequence and organization of the upstream region of the <i>Corynebacterium glutamicum lysA</i> gene," <i>Mol. Microbiol.</i> , 4(11):1819-1830 (1990)

Table 2 (continued)

X33994	trpL; trpE	Putative leader peptide; anthranilate synthase component 1	Heery, D.M. et al. "Nucleotide sequence of the <i>Corynebacterium glutamicum</i> trpE gene," <i>Nucleic Acids Res.</i> 18(23):7138 (1990)
X56037	thrC	Threonine synthase	Han, K.S. et al. "The molecular structure of the <i>Corynebacterium glutamicum</i> threonine synthase gene," <i>Mol. Microbiol.</i> , 4(10):1693-1702 (1990)
X56075	attB-related site	Attachment site	Cianciotto, N. et al. "DNA sequence homology between att B-related sites of <i>Corynebacterium diphtheriae</i> , <i>Corynebacterium ulcerans</i> , <i>Corynebacterium glutamicum</i> , and the attP site of <i>lambda</i> corynephage," <i>FEMS Microbiol. Lett.</i> , 66:299-302 (1990)
X57226	lysC-alpha; lysC-beta; asd	Aspartokinase-alpha subunit; Aspartokinase-beta subunit; aspartate beta semialdehyde dehydrogenase	Kalinowski, J. et al. "Genetic and biochemical analysis of the Aspartokinase from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 5(5):1197-1204 (1991); Kalinowski, J. et al. "Aspartokinase genes lysC alpha and lysC beta overlap and are adjacent to the aspartate beta-semialdehyde dehydrogenase gene and in <i>Corynebacterium glutamicum</i> ," <i>Mol. Gen. Genet.</i> , 224(3):317-324 (1990)
X59403	gap; pgk; tpi	Glyceraldehyde-3-phosphate; phosphoglycerate kinase; triosephosphate isomerase	Eikmanns, B.J. "Identification, sequence analysis, and expression of a <i>Corynebacterium glutamicum</i> gene cluster encoding the three glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase, 3-phosphoglycerate kinase, and triosephosphate isomeras," <i>J. Bacteriol.</i> , 174(19):6076-6086 (1992)
X59404	gdh	Glutamate dehydrogenase	Bormann, E.R. et al. "Molecular analysis of the <i>Corynebacterium glutamicum</i> gdh gene encoding glutamate dehydrogenase," <i>Mol. Microbiol.</i> , 6(3):317-326 (1992)
X60312	lysI	L-lysine permease	Seep-Feldhaus, A.H. et al. "Molecular analysis of the <i>Corynebacterium glutamicum</i> lysI gene involved in lysine uptake," <i>Mol. Microbiol.</i> , 5(12):2995-3005 (1991)
X66078	copI	PsI protein	Joliff, G. et al. "Cloning and nucleotide sequence of the csp1 gene encoding PsI, one of the two major secreted proteins of <i>Corynebacterium glutamicum</i> : The deduced N-terminal region of PsI is similar to the <i>Mycobacterium antigen 85</i> complex," <i>Mol. Microbiol.</i> , 6(16):2349-2362 (1992)
X66112	glt	Citrate synthase	Eikmanns, B.J. et al. "Cloning sequence, expression and transcriptional analysis of the <i>Corynebacterium glutamicum</i> gltA gene encoding citrate synthase," <i>Microbiol.</i> , 140:1817-1828 (1994)
X67737	dapB	Dihydrodipicolinate reductase	Peyret, J.L. et al. "Characterization of the cspB gene encoding PS2, an ordered surface-layer protein in <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 9(1):97-109 (1993)
X69103	esp2	Surface layer protein PS2	Bonamy, C. et al. "Identification of IS1206, a <i>Corynebacterium glutamicum</i> IS3-related insertion sequence and phylogenetic analysis," <i>Mol. Microbiol.</i> , 14(3):571-581 (1994)
X69104		IS3 related insertion element	

Table 2 (continued)

X70959	leuA	Isopropylmalate synthase	Patek, M. et al. "Leucine synthesis in <i>Corynebacterium glutamicum</i> : enzyme activities, structure of leuA, and effect of leuA inactivation on lysine synthesis," <i>Appl. Environ. Microbiol.</i> , 60(1):133-140 (1994)
X71489	icd	Isocitrate dehydrogenase (NADP+)	Eikmanns, B.J. et al. "Cloning, sequence analysis, expression, and inactivation of the <i>Corynebacterium glutamicum</i> icd gene encoding isocitrate dehydrogenase and biochemical characterization of the enzyme," <i>J. Bacteriol.</i> , 177(3):774-782 (1995)
X72855	GDHA	Glutamate dehydrogenase (NADP+)	Heery, D.M. et al. "A sequence from a tryptophan-hyperproducing strain of <i>Corynebacterium glutamicum</i> encoding resistance to S-methyltryptophan," <i>Biochem. Biophys. Res. Commun.</i> , 201(3):1255-1262 (1994)
X75083, X70584	mttA	S-methyltryptophan resistance	Fitzpatrick, R. et al. "Construction and characterization of recA mutant strains of <i>Corynebacterium glutamicum</i> and <i>Brevibacterium lactofermentum</i> ," <i>Appl. Microbiol. Biotechnol.</i> , 42(4):575-580 (1994)
X75085	recA		Reinscheid, D.J. et al. "Characterization of the isocitrate lyase gene from <i>Corynebacterium glutamicum</i> and biochemical analysis of the enzyme," <i>J. Bacteriol.</i> , 176(12):3474-3483 (1994)
X75504	aceA; thiX	Partial Isocitrate lyase; ?	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes," <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)
X76875		ATPase beta-subunit	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes," <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)
X77034	tuf	Elongation factor Tu	Billman-Jacobe, H. "Nucleotide sequence of a recA gene from <i>Corynebacterium glutamicum</i> ," <i>DNA Seq.</i> , 4(6):403-404 (1994)
X77384	recA		Reinscheid, D.J. et al. "Malate synthase from <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase: sequence analysis," <i>Microbiology</i> , 140:3099-3108 (1994)
X78491	aceB	Malate synthase	Rainey, F.A. et al. "Phylogenetic analysis of the genera <i>Rhodococcus</i> and <i>Nocardioides</i> and evidence for the evolutionary origin of the genus <i>Nocardioides</i> from within the radiation of <i>Rhodococcus</i> species," <i>Microbiol.</i> , 141:523-528 (1995)
X80629	16S rDNA	16S ribosomal RNA	Kronemeyer, W. et al. "Structure of the gluABCD cluster encoding the glutamate uptake system of <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 177(5):1152-1158 (1995)
X81191	gluA; gluB; gluC; gluD	Glutamate uptake system	Wehmann, A. et al. "Analysis of different DNA fragments of <i>Corynebacterium glutamicum</i> complementing dapE of <i>Escherichia coli</i> ," <i>Microbiology</i> , 140:3349-3356 (1994)
X81379	dapE	Succinylidiaminopimelate desuccinylase	

Table 2 (continued)

X82061	16S rDNA	16S ribosomal RNA	Ruimy, R. et al. "Phylogeny of the genus <i>Corynebacterium</i> deduced from analyses of small-subunit ribosomal DNA sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):740-746 (1995)
X82928	asd; lysC	Aspartate-semialdehyde dehydrogenase; ?	Serebrijski, I. et al. "Multicopy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X82929	proA	Gamma-glutamyl phosphate reductase	Serebrijski, I. et al. "Multicopy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X84257	16S rDNA	16S ribosomal RNA	Pascual, C. et al. "Phylogenetic analysis of the genus <i>Corynebacterium</i> based on 16S rRNA gene sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):724-728 (1995)
X83963	aroP; dapE	Aromatic amino acid permease; ?	Wehrmann et al. "Functional analysis of sequences adjacent to dapE of <i>C. glutamicum</i> proline reveals the presence of aroP, which encodes the aromatic amino acid transporter," <i>J. Bacteriol.</i> , 177(20):5991-5993 (1995)
X86137	argB; argC; argD; argF; argJ	Acetylglutamate kinase; N-acetyl-gamma-glutamyl-phosphate reductase; acetylornithine aminotransferase; ornithine carbamoyltransferase; glutamate N-acetyltransferase	Sakanyan, V. et al. "Genes and enzymes of the acetyl cycle of arginine biosynthesis in <i>Corynebacterium glutamicum</i> : enzyme evolution in the early steps of the arginine pathway," <i>Microbiology</i> , 142:99-108 (1996)
X89084	pta; ackA	Phosphate acetyltransferase; acetate kinase	Reinscheid, D.J. et al. "Cloning, sequence analysis, expression and inactivation of the <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase and acetate kinase," <i>Microbiology</i> , 145:503-513 (1999)
X89850	attB	Attachment site	Le Marrec, C. et al. "Genetic characterization of site-specific integration functions of phi AAU2 infecting "Aribrobacter aureus C70," <i>J. Bacteriol.</i> , 178(7):1996-2004 (1996)
X90356		Promoter fragment F1	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90357		Promoter fragment F2	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90358		Promoter fragment F10	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90359		Promoter fragment F13	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)

Table 2 (continued)

X90360	Promoter fragment F22	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90361	Promoter fragment F34	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90362	Promoter fragment F37	Patek, M. et al. "Promoters from <i>C. glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90363	Promoter fragment F45	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90364	Promoter fragment F64	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90365	Promoter fragment F75	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90366	Promoter fragment PF101	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90367	Promoter fragment PF104	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90368	Promoter fragment PF109	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X93513	amt	Siewe, R.M. et al. "Functional and genetic characterization of the (methyl) ammonium uptake carrier of <i>Corynebacterium glutamicum</i> ," <i>J. Biol. Chem.</i> , 271(10) 5398-5403 (1996)
X93514	betP	Peter, H. et al. "Isolation, characterization, and expression of the <i>Corynebacterium glutamicum</i> betP gene, encoding the transport system for the compatible solute glycine betaine," <i>J. Bacteriol.</i> , 178(17):5229-5234 (1996)
X95649	atf4	Patek, M. et al. "Identification and transcriptional analysis of the dapB-ORF2-dapA-ORF4 operon of <i>Corynebacterium glutamicum</i> , encoding two enzymes involved in L-lysine synthesis," <i>Biootechnol. Lett.</i> , 19:1113-1117 (1997)
X96471	lysE; lysG	Vrijic, M. et al. "A new type of transporter with a new type of cellular function: L-lysine export from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 22(5):815-826 (1996)

Table 2 (continued)

X96580	panB; panC; xy1B	3-methyl-2-oxobutanoate hydroxymethyltransferase; pantoate-beta-alanine ligase; xylulokinase	Sahm, H. et al. "D-pantothenate synthesis in <i>Corynebacterium glutamicum</i> and use of panBC and genes encoding L-valine synthesis for D-pantothenate overproduction," <i>Appl. Environ. Microbiol.</i> , 65(5): 1973-1979 (1999)
X96962		Insertion sequence IS1207 and transposase	
X99289		Elongation factor P	Ramos, A. et al. "Cloning, sequencing and expression of the gene encoding elongation factor P in the amino-acid producer <i>Brevibacterium lactofermentum</i> (<i>Corynebacterium glutamicum</i> ATCC 13869)," <i>Gene</i> , 198:217-222 (1997)
Y00140	thrB	Homoserine kinase	Mateos, L.M. et al. "Nucleotide sequence of the homoserine kinase (thrB) gene of the <i>Brevibacterium lactofermentum</i> ," <i>Nucleic Acids Res.</i> , 15(9):3922 (1987)
Y00151	ddh	Meso-diaminopimelate D-dehydrogenase (EC 1.4.1.16)	Ishino, S. et al. "Nucleotide sequence of the meso-diaminopimelate D-dehydrogenase gene from <i>Corynebacterium glutamicum</i> ," <i>Nucleic Acids Res.</i> , 15(9):3917 (1987)
Y00476	thrA	Homoserine dehydrogenase	Mateos, L.M. et al. "Nucleotide sequence of the homoserine dehydrogenase (thrA) gene of the <i>Brevibacterium lactofermentum</i> ," <i>Nucleic Acids Res.</i> , 15(24):10598 (1987)
Y00546	hom; thrB	Homoserine dehydrogenase; homoserine kinase	Peoples, O.P. et al. "Nucleotide sequence and fine structural analysis of the <i>Corynebacterium glutamicum</i> hom-thrB operon," <i>Mol. Microbiol.</i> , 2(1):63-72 (1988)
Y08964	murC; ftsQ/divD; ftsZ	UDP-N-acetylglucosamine ligase; division initiation protein or cell division protein; cell division protein	Honnibia, M.P. et al. "Identification, characterization, and chromosomal organization of the ftsZ gene from <i>Brevibacterium lactofermentum</i> ," <i>Mol. Gen. Genet.</i> , 259(1):97-104 (1998)
Y09163	putP	High affinity proline transport system	Peter, H. et al. "Isolation of the putP gene of <i>Corynebacterium glutamicum</i> and characterization of a low-affinity uptake system for compatible solutes," <i>Arch. Microbiol.</i> , 168(2):143-151 (1997)
Y09548	pyc	Pyruvate carboxylase	Peters-Wendisch, P.G. et al. "Pyruvate carboxylase from <i>Corynebacterium glutamicum</i> : characterization, expression and inactivation of the pyc gene," <i>Microbiology</i> , 144:915-927 (1998)
Y09578	leuB	3-isopropylmalate dehydrogenase	Patek, M. et al. "Analysis of the leuB gene from <i>Corynebacterium glutamicum</i> ," <i>Appl. Microbiol. Biotechnol.</i> , 50(1):42-47 (1998)
Y12472		Attachment site bacteriophage Phi-16	Moreau, S. et al. "Site-specific integration of corynephage Phi-16: The construction of an integration vector," <i>Microbiol.</i> , 145:539-548 (1999)
Y12337	proP	Proline/ectoine uptake system protein	Peter, H. et al. "Corynebacterium glutamicum is equipped with four secondary carriers for compatible solutes: Identification, sequencing, and characterization of the proline/ectoine uptake system, ProP, and the ectoine/proline/glycine betaine carrier, EcpP," <i>J. Bacteriol.</i> , 180(22):6005-6012 (1998)

Table 2 (continued)

Y13221	glnA	Glutamine synthetase I	Jakoby, M. et al. "Isolation of <i>Corynebacterium glutamicum</i> glnA gene encoding glutamine synthetase I," <i>FEBS Microbiol. Lett.</i> , 154(1):81-88 (1997)
Y16642	lpd	Dihydrolipoamide dehydrogenase	Attachment site <i>Corynephage 304L</i>
Y18059			Moreau, S. et al. "Analysis of the integration functions of φ304L: An integrase module among corynephages," <i>Virology</i> , 255(1):150-159 (1999)
221501	argS; lysA	Arginyl-tRNA synthetase; diaminopimelate decarboxylase (partial)	Oguiza, J.A. et al. "A gene encoding arginyl-tRNA synthetase is located in the upstream region of the lysA gene in <i>Brevibacterium lactofermentum</i> : Regulation of argS-lysA cluster expression by arginine," <i>J. Bacteriol.</i> , 175(22):7356-7362 (1993)
221502	dapA; dapB	Dihydridopicolinate synthase; dihydridopicolinate reductase	Pisabarro, A. et al. "A cluster of three genes (dapA, orf2, and dapB) of <i>Brevibacterium lactofermentum</i> encodes dihydridopicolinate reductase, and a third polypeptide of unknown function," <i>J. Bacteriol.</i> , 175(9):2743-2749 (1993)
229563	thrC	Threonine synthase	Malumbres, M. et al. "Analysis and expression of the thrC gene of the encoded threonine synthase," <i>Appl. Environ. Microbiol.</i> , 60(7):2209-2219 (1994)
246753	16S rDNA	Gene for 16S ribosomal RNA	Oguiza, J.A. et al. "Multiple sigma factor genes in <i>Brevibacterium lactofermentum</i> : Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
249822	sigA	SigA sigma factor	Oguiza, J.A. et al. "The galE gene encoding the UDP-galactose 4-epimerase of <i>Brevibacterium lactofermentum</i> is coupled transcriptionally to the dmdR gene," <i>Gene</i> , 177:103-107 (1996)
249823	galE; dtxR	Catalytic activity UDP-galactose 4-epimerase; diphtheria toxin regulatory protein	Oguiza, J.A. et al. "Multiple sigma factor genes in <i>Brevibacterium lactofermentum</i> : Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
249824	orf1; sigB	?; SigB sigma factor	Correia, A. et al. "Cloning and characterization of an IS-like element present in the genome of <i>Brevibacterium lactofermentum</i> ATCC 13869," <i>Gene</i> , 170(1):91-94 (1996)
266534		Transposase	A sequence for this gene was published in the indicated reference. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.

Exemplification**Example 1: Preparation of total genomic DNA of *Corynebacterium glutamicum* ATCC 13032**

5 A culture of *Corynebacterium glutamicum* (ATCC 13032) was grown overnight at 30°C with vigorous shaking in BHI medium (Difco). The cells were harvested by centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture — all indicated volumes have been calculated for 100 ml of culture volume). Composition of buffer-I: 140.34 g/l sucrose, 10 2.46 g/l MgSO₄ x 7H₂O, 10 ml/l KH₂PO₄ solution (100 g/l, adjusted to pH 6.7 with KOH), 50 ml/l M12 concentrate (10 g/l (NH₄)₂SO₄, 1 g/l NaCl, 2 g/l MgSO₄ x 7H₂O, 0.2 g/l CaCl₂, 0.5 g/l yeast extract (Difco), 10 ml/l trace-elements-mix (200 mg/l FeSO₄ x H₂O, 10 mg/l ZnSO₄ x 7 H₂O, 3 mg/l MnCl₂ x 4 H₂O, 30 mg/l H₃BO₃, 20 mg/l CoCl₂ x 6 H₂O, 1 mg/l NiCl₂ x 6 H₂O, 3 mg/l Na₂MoO₄ x 2 H₂O, 500 mg/l complexing agent 15 (EDTA or citric acid), 100 ml/l vitamins-mix (0.2 mg/l biotin, 0.2 mg/l folic acid, 20 mg/l p-amino benzoic acid, 20 mg/l riboflavin, 40 mg/l ca-panthothenate, 140 mg/l nicotinic acid, 40 mg/l pyridoxole hydrochloride, 200 mg/l myo-inositol). Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml. After an approximately 4 h incubation at 37°C, the cell wall was degraded and the resulting 20 protoplasts are harvested by centrifugation. The pellet was washed once with 5 ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml NaCl solution (5 M) are added. After adding of proteinase K to a final concentration of 25 200 µg/ml, the suspension is incubated for ca. 18 h at 37°C. The DNA was purified by extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform-isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min 30 incubation at -20°C and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall). The DNA was dissolved in 1 ml TE-buffer containing 20 µg/ml RNaseA and dialysed at 4°C against 1000 ml TE-buffer for at least 3 hours. During this time, the buffer was exchanged 3 times. To aliquots of 0.4 ml of the dialysed DNA solution, 0.4 ml of 2 M LiCl and 0.8 ml of ethanol are added. After a 30

min incubation at -20°C, the DNA was collected by centrifugation (13,000 rpm, Biofuge Fresco, Heraeus, Hanau, Germany). The DNA pellet was dissolved in TE-buffer. DNA prepared by this procedure could be used for all purposes, including southern blotting or construction of genomic libraries.

5

Example 2: Construction of genomic libraries in *Escherichia coli* of *Corynebacterium glutamicum* ATCC13032.

Using DNA prepared as described in Example 1, cosmid and plasmid libraries were constructed according to known and well established methods (see e.g., Sambrook, J. et al.

10 (1989) "Molecular Cloning : A Laboratory Manual", Cold Spring Harbor Laboratory Press, or Ausubel, F.M. et al. (1994) "Current Protocols in Molecular Biology", John Wiley & Sons.)

Any plasmid or cosmid could be used. Of particular use were the plasmids pBR322 (Sutcliffe, J.G. (1979) *Proc. Natl. Acad. Sci. USA*, 75:3737-3741); pACYC177 (Change & 15 Cohen (1978) *J. Bacteriol.* 134:1141-1156), plasmids of the pBS series (pBSSK+, pBSSK- and others; Stratagene, LaJolla, USA), or cosmids as SuperCos1 (Stratagene, LaJolla, USA) or Lorist6 (Gibson, T.J., Rosenthal A. and Waterson, R.H. (1987) *Gene* 53:283-286. Gene libraries specifically for use in *C. glutamicum* may be constructed using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

20

Example 3: DNA Sequencing and Computational Functional Analysis

Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using ABI377 sequencing machines (see e.g., Fleischman, R.D. et al. (1995) "Whole-genome

25 Random Sequencing and Assembly of *Haemophilus Influenzae* Rd., *Science*, 269:496-512). Sequencing primers with the following nucleotide sequences were used: 5'-GGAAACAGTATGACCATG-3' or 5'-GTAAAACGACGGCCAGT-3'.

Example 4: *In vivo* Mutagenesis

30 *In vivo* mutagenesis of *Corynebacterium glutamicum* can be performed by passage of plasmid (or other vector) DNA through *E. coli* or other microorganisms (e.g. *Bacillus* spp. or yeasts such as *Saccharomyces cerevisiae*) which are impaired in their capabilities to maintain

the integrity of their genetic information. Typical mutator strains have mutations in the genes for the DNA repair system (e.g., mutHLS, mutD, mutT, etc.; for reference, see Rupp, W.D. (1996) DNA repair mechanisms, in: *Escherichia coli and Salmonella*, p. 2277-2294, ASM: Washington.) Such strains are well known to those of ordinary skill in the art. The use of such 5 strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) *Strategies* 7: 32-34.

Example 5: DNA Transfer Between *Escherichia coli* and *Corynebacterium glutamicum*

Several *Corynebacterium* and *Brevibacterium* species contain endogenous 10 plasmids (as e.g., pHM1519 or pBL1) which replicate autonomously (for review see, e.g., Martin, J.F. et al. (1987) *Biotechnology*, 5:137-146). Shuttle vectors for *Escherichia coli* and *Corynebacterium glutamicum* can be readily constructed by using standard vectors for *E. coli* (Sambrook, J. et al. (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press or Ausubel, F.M. et al. (1994) "Current Protocols in 15 Molecular Biology", John Wiley & Sons) to which a origin or replication for and a suitable marker from *Corynebacterium glutamicum* is added. Such origins of replication are preferably taken from endogenous plasmids isolated from *Corynebacterium* and *Brevibacterium* species. Of particular use as transformation markers for these species are genes for kanamycin resistance (such as those derived from the Tn5 or Tn903 20 transposons) or chloramphenicol (Winnacker, E.L. (1987) "From Genes to Clones — Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both *E. coli* and *C. glutamicum*, and which can be used for several purposes, including gene over-expression (for reference, see e.g., Yoshihama, M. et al. (1985) *J. Bacteriol.* 162:591-597, 25 Martin J.F. et al. (1987) *Biotechnology*, 5:137-146 and Eikmanns, B.J. et al. (1991) *Gene*, 102:93-98).

Using standard methods, it is possible to clone a gene of interest into one of the 30 shuttle vectors described above and to introduce such a hybrid vectors into strains of *Corynebacterium glutamicum*. Transformation of *C. glutamicum* can be achieved by protoplast transformation (Kastsumata, R. et al. (1984) *J. Bacteriol.* 159:306-311), electroporation (Liebl, E. et al. (1989) *FEMS Microbiol. Letters*, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schäfer, A et al.

(1990) *J. Bacteriol.* 172:1663-1666). It is also possible to transfer the shuttle vectors for *C. glutamicum* to *E. coli* by preparing plasmid DNA from *C. glutamicum* (using standard methods well-known in the art) and transforming it into *E. coli*. This transformation step can be performed using standard methods, but it is advantageous to use an *Mcr*-deficient 5 *E. coli* strain, such as NM522 (Gough & Murray (1983) *J. Mol. Biol.* 166:1-19).

Genes may be overexpressed in *C. glutamicum* strains using plasmids which comprise pCG1 (U.S. Patent No. 4,617,267) or fragments thereof, and optionally the gene for kanamycin resistance from TN903 (Grindley, N.D. and Joyce, C.M. (1980) *Proc. Natl. Acad. Sci. USA* 77(12): 7176-7180). In addition, genes may be 10 overexpressed in *C. glutamicum* strains using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

Aside from the use of replicative plasmids, gene overexpression can also be achieved by integration into the genome. Genomic integration in *C. glutamicum* or other *Corynebacterium* or *Brevibacterium* species may be accomplished by well-known 15 methods, such as homologous recombination with genomic region(s), restriction endonuclease mediated integration (REMI) (see, e.g., DE Patent 19823834), or through the use of transposons. It is also possible to modulate the activity of a gene of interest by modifying the regulatory regions (e.g., a promoter, a repressor, and/or an enhancer) by sequence modification, insertion, or deletion using site-directed methods (such as 20 homologous recombination) or methods based on random events (such as transposon mutagenesis or REMI). Nucleic acid sequences which function as transcriptional terminators may also be inserted 3' to the coding region of one or more genes of the invention; such terminators are well-known in the art and are described, for example, in Winnacker, E.L. (1987) *From Genes to Clones – Introduction to Gene Technology*. VCH: 25 Weinheim.

Example 6: Assessment of the Expression of the Mutant Protein

Observations of the activity of a mutated protein in a transformed host cell rely on the fact that the mutant protein is expressed in a similar fashion and in a similar quantity 30 to that of the wild-type protein. A useful method to ascertain the level of transcription of the mutant gene (an indicator of the amount of mRNA available for translation to the gene product) is to perform a Northern blot (for reference see, for example, Ausubel *et al.*

- 122 -

(1988) *Current Protocols in Molecular Biology*, Wiley: New York), in which a primer designed to bind to the gene of interest is labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the 5 binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the mutant gene. Total cellular RNA can be prepared from *Corynebacterium glutamicum* by several methods, all well-known in the art, such as that described in Bormann, E.R. *et al.* (1992) *Mol. Microbiol.* 6: 317-326.

10 To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel *et al.* (1988) *Current Protocols in Molecular Biology*, Wiley: New York). In this process, total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which 15 specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and quantity of label observed indicates the presence and quantity of the desired mutant protein present in the cell.

20 **Example 7: Growth of Genetically Modified *Corynebacterium glutamicum* — Media and Culture Conditions**

Genetically modified *Corynebacteria* are cultured in synthetic or natural growth media. A number of different growth media for *Corynebacteria* are both well-known and readily available (Lieb *et al.* (1989) *Appl. Microbiol. Biotechnol.*, 32:205-210; von der 25 Osten *et al.* (1998) *Biotechnology Letters*, 11:11-16; Patent DE 4,120,867; Liebl (1992) "The Genus *Corynebacterium*, in: *The Prokaryotes, Volume II*, Balows, A. *et al.*, eds. Springer-Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose, 30 ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex compounds such as molasses or other by-products from sugar refinement. It can also be

advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or 5 ammonia salts, such as NH₄Cl or (NH₄)₂SO₄, NH₄OH, nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.

Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt, 10 molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as 15 vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on the immediate experiment and is individually decided for each specific case. Information 20 about media optimization is available in the textbook "Applied Microbiol. Physiology, A Practical Approach (eds. P.M. Rhodes, P.F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3). It is also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others.

All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration. The components can either be sterilized together or, if 25 necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.

Culture conditions are defined separately for each experiment. The temperature should be in a range between 15°C and 45°C. The temperature can be kept constant or can be altered during the experiment. The pH of the medium should be in the range of 5 to 30 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media. An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It

is also possible to maintain a constant culture pH through the addition of NaOH or NH₄OH during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the micro-
5 organisms, the pH can also be controlled using gaseous ammonia.

The incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes.
10 For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 – 300 rpm. Evaporation losses can be diminished by the maintenance
15 of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.

If genetically modified clones are tested, an unmodified control clone or a control clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an OD₆₀₀ of 0.5 – 1.5 using cells grown on agar plates, such as CM plates
20 (10 g/l glucose, 2.5 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C. Inoculation of the media is accomplished by either introduction of a saline suspension of *C. glutamicum* cells from CM plates or addition of a liquid preculture of this bacterium.
25

Example 8 – *In vitro* Analysis of the Function of Mutant Proteins

The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered enzyme must be tailored to the specific activity of the wild-type enzyme, which is well
30 within the ability of one of ordinary skill in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be

found, for example, in the following references: Dixon, M., and Webb, E.C., (1979) *Enzymes*. Longmans: London; Fersht, (1985) *Enzyme Structure and Mechanism*. Freeman: New York; Walsh, (1979) *Enzymatic Reaction Mechanisms*. Freeman: San Francisco; Price, N.C., Stevens, L. (1982) *Fundamentals of Enzymology*. Oxford Univ. Press: Oxford; Boyer, P.D., ed. (1983) *The Enzymes*, 3rd ed. Academic Press: New York; Bisswanger, H., (1994) *Enzymkinetik*, 2nd ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H.U., Bergmeyer, J., Graßl, M., eds. (1983-1986) *Methods of Enzymatic Analysis*, 3rd ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann's *Encyclopedia of Industrial Chemistry* (1987) vol. A9, "Enzymes". VCH: Weinheim, p. 10 352-363.

The activity of proteins which bind to DNA can be measured by several well-established methods, such as DNA band-shift assayss (also called gel retardation assays). The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. *et al.* (1995) *EMBO J.* 14: 15 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others.

The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R.B. (1989) "Pores, 20 Channels and Transporters", in *Biomembranes, Molecular Structure and Function*, Springer: Heidelberg, p. 85-137; 199-234; and 270-322.

Example 9: Analysis of Impact of Mutant Protein on the Production of the Desired Product

25 The effect of the genetic modification in *C. glutamicum* on production of a desired compound (such as an amino acid) can be assessed by growing the modified microorganism under suitable conditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (*i.e.*, an amino acid). Such analysis techniques are well known to one of 30 ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example,

- 126 -

Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A. *et al.*, (1987) "Applications of HPLC in Biochemistry" in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm *et al.* (1993) Biotechnology, vol. 3, Chapter III: "Product recovery and purification", page 5 469-714, VCH: Weinheim; Belter, P.A. *et al.* (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J.F. and Cabral, J.M.S. (1992) Recovery processes for biological materials, John Wiley and Sons; Shaeiwitz, J.A. and Henry, J.D. (1988) Biochemical separations, in: Ullmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow, 10 F.J. (1989) Separation and purification techniques in biotechnology, Noyes Publications.)

In addition to the measurement of the final product of fermentation, it is also possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to 15 determine the overall efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (e.g., sugars, hydrocarbons, nitrogen sources, phosphate, and other ions), measurements of biomass composition and growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced during fermentation. Standard methods for these 20 measurements are outlined in Applied Microbial Physiology, A Practical Approach, P.M. Rhodes and P.F. Stanbury, eds., IRL Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein.

Example 10: Purification of the Desired Product from *C. glutamicum* Culture

25 Recovery of the desired product from the *C. glutamicum* cells or supernatant of the above-described culture can be performed by various methods well known in the art. If the desired product is not secreted from the cells, the cells can be harvested from the culture by low-speed centrifugation, the cells can be lysed by standard techniques, such as mechanical force or sonication. The cellular debris is removed by centrifugation, and 30 the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the *C. glutamicum*

cells, then the cells are removed from the culture by low-speed centrifugation, and the supernate fraction is retained for further purification.

The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on a chromatography resin while many of the impurities in the sample are not, or where the impurities are retained by the resin while the sample is not. Such chromatography steps may be repeated as necessary, using the same or different chromatography resins. One of ordinary skill in the art would be well-versed in the selection of appropriate chromatography resins and in their most efficacious application for a particular molecule to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized.

There are a wide array of purification methods known to the art and the preceding method of purification is not meant to be limiting. Such purification techniques are described, for example, in Bailey, J.E. & Ollis, D.F. *Biochemical Engineering Fundamentals*, McGraw-Hill: New York (1986).

The identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high-performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic assay, or microbiologically. Such analysis methods are reviewed in: Patek *et al.* (1994) *Appl. Environ. Microbiol.* 60: 133-140; Malakhova *et al.* (1996) *Biotehnologiya* 11: 27-32; and Schmidt *et al.* (1998) *Bioprocess Engineer.* 19: 67-70. Ulmann's Encyclopedia of Industrial Chemistry, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540-547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, John Wiley and Sons; Fallon, A. *et al.* (1987) *Applications of HPLC in Biochemistry* in: *Laboratory Techniques in Biochemistry and Molecular Biology*, vol. 17.

Example 11: Analysis of the Gene Sequences of the Invention

The comparison of sequences and determination of percent homology between two sequences are art-known techniques, and can be accomplished using a mathematical algorithm, such as the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-68, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA*

90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to SMP nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to SMP protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, one of ordinary skill in the art will know how to optimize the parameters of the program (e.g., XBLAST and NBLAST) for the specific sequence being analyzed.

Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Meyers and Miller ((1988) *Comput. Appl. Biosci.* 4: 11-17). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art, and include ADVANCE and ADAM, described in Torelli and Robotti (1994) *Comput. Appl. Biosci.* 10:3-5; and FASTA, described in Pearson and Lipman (1988) *P.N.A.S.* 85:2444-8.

The percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. The percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using standard parameters, such as a gap weight of 50 and a length weight of 3.

A comparative analysis of the gene sequences of the invention with those present in Genbank has been performed using techniques known in the art (see, e.g., Bexevanis and Ouellette, eds. (1998) *Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins*. John Wiley and Sons: New York). The gene sequences of the invention

were compared to genes present in Genbank in a three-step process. In a first step, a BLASTN analysis (e.g., a local alignment analysis) was performed for each of the sequences of the invention against the nucleotide sequences present in Genbank, and the top 500 hits were retained for further analysis. A subsequent FASTA search (e.g., a 5 combined local and global alignment analysis, in which limited regions of the sequences are aligned) was performed on these 500 hits. Each gene sequence of the invention was subsequently globally aligned to each of the top three FASTA hits, using the GAP program in the GCG software package (using standard parameters). In order to obtain correct results, the length of the sequences extracted from Genbank were adjusted to the 10 length of the query sequences by methods well-known in the art. The results of this analysis are set forth in Table 4. The resulting data is identical to that which would have been obtained had a GAP (global) analysis alone been performed on each of the genes of the invention in comparison with each of the references in Genbank, but required significantly reduced computational time as compared to such a database-wide GAP 15 (global) analysis. Sequences of the invention for which no alignments above the cutoff values were obtained are indicated on Table 4 by the absence of alignment information. It will further be understood by one of ordinary skill in the art that the GAP alignment homology percentages set forth in Table 4 under the heading "% homology (GAP)" are listed in the European numerical format, wherein a ',' represents a decimal point. For 20 example, a value of "40,345" in this column represents "40.345%".

Example 12: Construction and Operation of DNA Microarrays

The sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are 25 well known in the art, and are described, for example, in Schena, M. *et al.* (1995) *Science* 270: 467-470; Wodicka, L. *et al.* (1997) *Nature Biotechnology* 15: 1359-1367; DeSaizieu, A. *et al.* (1998) *Nature Biotechnology* 16: 45-48; and DeRisi, J.L. *et al.* (1997) *Science* 278: 680-686).

DNA microarrays are solid or flexible supports consisting of nitrocellulose, 30 nylon, glass, silicone, or other materials. Nucleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label

may be used to monitor and measure the individual signal intensities of the hybridized molecules at defined regions. This methodology allows the simultaneous quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. DNA microarrays, therefore, permit an analysis of the 5 expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, e.g., Schena, M. (1996) *BioEssays* 18(5): 427-431).

The sequences of the invention may be used to design oligonucleotide primers which are able to amplify defined regions of one or more *C. glutamicum* genes by a nucleic acid amplification reaction such as the polymerase chain reaction. The choice 10 and design of the 5' or 3' oligonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. et al. (1995) *Science* 270: 467-470).

Nucleic acid microarrays may also be constructed by *in situ* oligonucleotide 15 synthesis as described by Wodicka, L. et al. (1997) *Nature Biotechnology* 15: 1359-1367. By photolithographic methods, precisely defined regions of the matrix are exposed to light. Protective groups which are photolabile are thereby activated and undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the 20 synthesis of different oligonucleotides at defined positions. Small, defined regions of the genes of the invention may be synthesized on microarrays by solid phase oligonucleotide synthesis.

The nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays. These nucleic acid molecules can be 25 labeled according to standard methods. In brief, nucleic acid molecules (e.g., mRNA molecules or DNA molecules) are labeled by the incorporation of isotopically or fluorescently labeled nucleotides, e.g., during reverse transcription or DNA synthesis. Hybridization of labeled nucleic acids to microarrays is described (e.g., in Schena, M. et al. (1995) *supra*; Wodicka, L. et al. (1997), *supra*; and DeSaizieu A. et al. (1998), 30 *supra*). The detection and quantification of the hybridized molecule are tailored to the specific incorporated label. Radioactive labels can be detected, for example, as

- 131 -

described in Schena, M. *et al.* (1995) *supra*) and fluorescent labels may be detected, for example, by the method of Shalon *et al.* (1996) *Genome Research* 6: 639-645).

The application of the sequences of the invention to DNA microarray technology, as described above, permits comparative analyses of different strains of *C. glutamicum* or other *Corynebacteria*. For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the invention during the course of a fermentation reaction are possible using nucleic acid array technology.

Example 13: Analysis of the Dynamics of Cellular Protein Populations (Proteomics)

The genes, compositions, and methods of the invention may be applied to study the interactions and dynamics of populations of proteins, termed 'proteomics'. Protein populations of interest include, but are not limited to, the total protein population of *C. glutamicum* (e.g., in comparison with the protein populations of other organisms), those proteins which are active under specific environmental or metabolic conditions (e.g., during fermentation, at high or low temperature, or at high or low pH), or those proteins which are active during specific phases of growth and development.

Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis. Cellular proteins may be obtained, for example, by lysis or extraction, and may be separated from one another using a variety of electrophoretic techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins largely on the basis of their molecular weight. Isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein). Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann *et al.* (1998) *Electrophoresis* 19: 3217-3221; Fountoulakis *et al.* (1998) *Electrophoresis* 19: 1193-1202; Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192; Antelmann *et al.* (1997) *Electrophoresis* 18:

1451-1463). Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art.

Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and 5 include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes). The inclusion of radioactively labeled amino acids or other protein precursors (e.g., ³⁵S-methionine, ³⁵S-cysteine, ¹⁴C-labelled amino acids, ¹⁵N-amino acids, ¹⁵NO₃ or ¹⁵NH₄⁺ or ¹³C-labelled amino acids) in the medium of *C. glutamicum* permits the labeling of proteins from these cells prior to their separation. Similarly, 10 fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated according to the previously described techniques.

Proteins visualized by these techniques can be further analyzed by measuring the amount of dye or label used. The amount of a given protein can be determined 15 quantitatively using, for example, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and screens. Such techniques are well-known in the art.

To determine the identity of any given protein, direct sequencing or other 20 standard techniques may be employed. For example, N- and/or C-terminal amino acid sequencing (such as Edman degradation) may be used, as may mass spectrometry (in particular MALDI or ESI techniques (see, e.g., Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192)). The protein sequences provided herein can be used for the identification 25 of *C. glutamicum* proteins by these techniques.

The information obtained by these methods can be used to compare patterns of 30 protein presence, activity, or modification between different samples from various biological conditions (e.g., different organisms, time points of fermentation, media conditions, or different biotopes, among others). Data obtained from such experiments alone, or in combination with other techniques, can be used for various applications, such as to compare the behavior of various organisms in a given (e.g., metabolic) situation, to increase the productivity of strains which produce fine chemicals or to increase the efficiency of the production of fine chemicals.

Equivalents

Those of ordinary skill in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of 5 the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed:

1. An isolated nucleic acid molecule from *Corynebacterium glutamicum* encoding an SMP protein, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
2. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes an SMP protein involved in the production of a fine chemical.
3. An isolated *Corynebacterium glutamicum* nucleic acid molecule selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
4. An isolated nucleic acid molecule which encodes a polypeptide sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
5. An isolated nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide selected from the group of amino acid sequences consisting of those sequences set forth in as even-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
6. An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleotide sequence selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.

7. An isolated nucleic acid molecule comprising a fragment of at least 15 nucleotides of a nucleic acid comprising a nucleotide sequence selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOS of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated genes set forth in Table 1.
8. An isolated nucleic acid molecule which hybridizes to the nucleic acid molecule of any one of claims 1-7 under stringent conditions.
- 10 9. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 1-8 or a portion thereof and a nucleotide sequence encoding a heterologous polypeptide.
10. A vector comprising the nucleic acid molecule of any one of claims 1-9.
- 15 11. The vector of claim 10, which is an expression vector.
12. A host cell transfected with the expression vector of claim 11.
- 20 13. The host cell of claim 12, wherein said cell is a microorganism.
14. The host cell of claim 13, wherein said cell belongs to the genus *Corynebacterium* or *Brevibacterium*.
- 25 15. The host cell of claim 12, wherein the expression of said nucleic acid molecule results in the modulation in production of a fine chemical from said cell.
16. The host cell of claim 15, wherein said fine chemical is selected from the group consisting of: organic acids, proteinogenic and nonproteinogenic amino acids, purine and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides, and enzymes.

17. A method of producing a polypeptide comprising culturing the host cell of claim 12 in an appropriate culture medium to, thereby, produce the polypeptide.
- 5 18. An isolated SMP polypeptide from *Corynebacterium glutamicum*, or a portion thereof.
19. The polypeptide of claim 18, wherein said polypeptide is involved in the production of a fine chemical.
- 10 20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.
- 15 21. An isolated polypeptide comprising a naturally occurring allelic variant of a polypeptide comprising an amino acid sequence selected from the group consisting of those sequences set forth as even-numbered SEQ ID NOs of the Sequence Listing, or a portion thereof, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.
- 20 22. The isolated polypeptide of any of claims 18-21, further comprising heterologous amino acid sequences.
- 25 23. An isolated polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 50% homologous to a nucleic acid selected from the group consisting of those sequences set forth as odd-numbered SEQ ID NOs of the Sequence Listing, provided that the nucleic acid molecule does not consist of any of the F-designated nucleic acid molecules set forth in Table 1.
- 30 24. An isolated polypeptide comprising an amino acid sequence which is at least 50% homologous to an amino acid sequence selected from the group consisting of those

sequences as even-numbered SEQ ID NOs of the Sequence Listing, provided that the amino acid sequence is not encoded by any of the F-designated genes set forth in Table 1.

5 25. A method for producing a fine chemical, comprising culturing a cell containing a vector of claim 12 such that the fine chemical is produced.

26. The method of claim 25, wherein said method further comprises the step of recovering the fine chemical from said culture.

10 27. The method of claim 25, wherein said method further comprises the step of transfecting said cell with the vector of claim 11 to result in a cell containing said vector.

15 28. The method of claim 25, wherein said cell belongs to the genus *Corynebacterium* or *Brevibacterium*.

20 29. The method of claim 25, wherein said cell is selected from the group consisting of: *Corynebacterium glutamicum*, *Corynebacterium herculis*, *Corynebacterium lilium*, *Corynebacterium acetoacidophilum*, *Corynebacterium acetoglutamicum*, *Corynebacterium acetophilum*, *Corynebacterium ammoniagenes*, *Corynebacterium fujikense*, *Corynebacterium nitrilophilus*, *Brevibacterium ammoniagenes*, *Brevibacterium butanicum*, *Brevibacterium divaricatum*, *Brevibacterium flavum*, *Brevibacterium healii*, *Brevibacterium ketoglutamicum*, *Brevibacterium ketosoreductum*, *Brevibacterium lactofermentum*, *Brevibacterium linens*, *Brevibacterium paraffinolyticum*, and those strains set forth in Table 3.

25 30. The method of claim 25, wherein expression of the nucleic acid molecule from said vector results in modulation of production of said fine chemical.

30 31. The method of claim 25, wherein said fine chemical is selected from the group consisting of: organic acids, proteinogenic and nonproteinogenic amino acids, purine

and pyrimidine bases, nucleosides, nucleotides, lipids, saturated and unsaturated fatty acids, diols, carbohydrates, aromatic compounds, vitamins, cofactors, polyketides, and enzymes.

5 32. The method of claim 25, wherein said fine chemical is an amino acid.

33. The method of claim 32, wherein said amino acid is drawn from the group consisting of: lysine, glutamate, glutamine, alanine, aspartate, glycine, serine, threonine, methionine, cysteine, valine, leucine, isoleucine, arginine, proline, histidine, 10 tyrosine, phenylalanine, and tryptophan.

34. A method for producing a fine chemical, comprising culturing a cell whose genomic DNA has been altered by the inclusion of a nucleic acid molecule of any one of claims 1-9.

15 35. A method for diagnosing the presence or activity of *Corynebacterium diphtheriae* in a subject, comprising detecting the presence of one or more of SEQ ID NOS 1 through 782 of the Sequence Listing in the subject, provided that the sequences are not or are not encoded by any of the F-designated sequences set forth in Table 1, 20 thereby diagnosing the presence or activity of *Corynebacterium diphtheriae* in the subject.

36. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOS of the 25 Sequence Listing, wherein the nucleic acid molecule is disrupted.

35. 37. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOS in the Sequence Listing, wherein the nucleic acid molecule comprises one or more 30 nucleic acid modifications from the sequence set forth as odd-numbered SEQ ID NOS of the Sequence Listing s.

38. A host cell comprising a nucleic acid molecule selected from the group consisting of the nucleic acid molecules set forth as odd-numbered SEQ ID NOS of the Sequence Listing, wherein the regulatory region of the nucleic acid molecule is modified 5 relative to the wild-type regulatory region of the molecule.

Thr Asp Ser Ser Val Ala Pro Pro Gly Gly Glu Ser Leu Gln Thr Val
 290 295 300
 Asn Arg Arg Val Lys Lys Ala Arg Glu Ser Leu Gln Arg Glu Tyr Gly
 305 310 315 320
 Ala Ala Asn Val Leu Val Val Ser His Val Thr Pro Ile Lys Ala Ile
 325 330 335
 Met Arg Gln Ala Leu Asp Ala Gly Pro Ser Phe Phe Gln Lys Ala His
 340 345 350
 Leu Asp Leu Ala Ser Leu Ser Ile Ala Glu Phe Tyr Glu Asp Gly Pro
 355 360 365
 Thr Cys Val Arg Leu Phe Asn Asp Thr Ser His Leu Glu Ala
 370 375 380

<210> 47

<211> 840

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (101)..(817)

<223> RXA02492

<400> 47

gctgtacaac gacgctattg ccaacgaaaa tgcgacgg gaaacgcattt acggctaaat 60

aaacgcgcgt cgtggAACAT aaagtggcaa actatgtacccat atg act aac gga aaa 115
Met Thr Asn Gly Lys
1 5ttg att ctt ctt cgt cac ggt cag agc gaa tgg aac gca tcc aac cag 163
Leu Ile Leu Leu Arg His Gly Gln Ser Glu Trp Asn Ala Ser Asn Gln
10 15 20ttc act gga tgg gtc gac gtc aat ctg acc gaa cag ggt gag gct gag 211
Phe Thr Gly Trp Val Asp Val Asn Leu Thr Glu Gln Gly Glu Ala Glu
25 30 35gcc aaa ggc gtc ctc cca ggc gtt gta tac acc tcc ttg ctg cgt cgc 259
Ala Lys Gly Val Leu Pro Gly Val Val Tyr Thr Ser Leu Leu Arg Arg
40 45 50gcg atc cgc act gca aac atc gca ctg aac gct gca gac cgc cac tgg 307
Ala Ile Arg Thr Ala Asn Ile Ala Leu Asn Ala Ala Asp Arg His Trp
55 60 65atc cca gtg atc cgc gac tgg cgc ctc aac gag cgt cac tac ggc gca 355
Ile Pro Val Ile Arg Asp Trp Arg Leu Asn Glu Arg His Tyr Gly Ala
70 75 80 85ctg cag ggc ctt gac aag gct gca acc aag gaa aaa tac ggc gac gac 403
Leu Gln Gly Leu Asp Lys Ala Ala Thr Lys Glu Lys Tyr Gly Asp Asp
90 95 100

cag ttc atg gaa tgg cgc cgc tcc tac gac acc cca cca cca gag ctc	451
Gln Phe Met Glu Trp Arg Arg Ser Tyr Asp Thr Pro Pro Pro Glu Leu	
105 110 115	
gcg gat gac gca gag tac tcc cag gca aat gac cct cgt tac gcg gac	499
Ala Asp Asp Ala Glu Tyr Ser Gln Ala Asn Asp Pro Arg Tyr Ala Asp	
120 125 130	
ctc gac gta gtt cca cgc acc gaa tgc ctc aag gac gtt gtg gtt cgt	547
Leu Asp Val Val Pro Arg Thr Glu Cys Leu Lys Asp Val Val Val Arg	
135 140 145	
ttt gtt cct tac ttc gag gaa gaa atc ctg cca cgc gca aag aag ggc	595
Phe Val Pro Tyr Phe Glu Glu Ile Leu Pro Arg Ala Lys Lys Gly	
150 155 160 165	
gaa acc gtc ctc atc gca gca cac ggc aac tcc ctg cgt gcg ctg gtt	643
Glu Thr Val Leu Ile Ala Ala His Gly Asn Ser Leu Arg Ala Leu Val	
170 175 180	
aag cac ctt gac ggc atc tcc gat gct gat atc gca gag ctc aac atc	691
Lys His Leu Asp Gly Ile Ser Asp Ala Asp Ile Ala Glu Leu Asn Ile	
185 190 195	
cca acc ggc atc cca ctg gtc tac gaa atc gcc gaa gac ggt tcc gta	739
Pro Thr Gly Ile Pro Leu Val Tyr Glu Ile Ala Glu Asp Gly Ser Val	
200 205 210	
gta aac cca ggc ggc acc tac ctc gat cct gag gca gca gca gca ggc	787
Val Asn Pro Gly Gly Thr Tyr Leu Asp Pro Glu Ala Ala Ala Ala Gly	
215 220 225	
gca gca gca gta gca aac cag ggt aat aag tagctatgg taggtgagca	837
Ala Ala Ala Val Ala Asn Gln Gly Asn Lys	
230 235	
ctc	840

<210> 48
 <211> 239
 <212> PRT

<213> *Corynebacterium glutamicum*

<400> 48	
Met Thr Asn Gly Lys Leu Ile Leu Leu Arg His Gly Gln Ser Glu Trp	
1 5 10 15	
Asn Ala Ser Asn Gln Phe Thr Gly Trp Val Asp Val Asn Leu Thr Glu	
20 25 30	
Gln Gly Glu Ala Glu Ala Lys Gly Val Leu Pro Gly Val Val Tyr Thr	
35 40 45	
Ser Leu Leu Arg Arg Ala Ile Arg Thr Ala Asn Ile Ala Leu Asn Ala	
50 55 60	
Ala Asp Arg His Trp Ile Pro Val Ile Arg Asp Trp Arg Leu Asn Glu	
65 70 75 80	
Arg His Tyr Gly Ala Leu Gln Gly Leu Asp Lys Ala Ala Thr Lys Glu	

85

90

95

Lys Tyr Gly Asp Asp Gln Phe Met Glu Trp Arg Arg Ser Tyr Asp Thr
 100 105 110

Pro Pro Pro Glu Leu Ala Asp Asp Ala Glu Tyr Ser Gln Ala Asn Asp
 115 120 125

Pro Arg Tyr Ala Asp Leu Asp Val Val Pro Arg Thr Glu Cys Leu Lys
 130 135 140

Asp Val Val Val Arg Phe Val Pro Tyr Phe Glu Glu Glu Ile Leu Pro
 145 150 155 160

Arg Ala Lys Lys Gly Glu Thr Val Leu Ile Ala Ala His Gly Asn Ser
 165 170 175

Leu Arg Ala Leu Val Lys His Leu Asp Gly Ile Ser Asp Ala Asp Ile
 180 185 190

Ala Glu Leu Asn Ile Pro Thr Gly Ile Pro Leu Val Tyr Glu Ile Ala
 195 200 205

Glu Asp Gly Ser Val Val Asn Pro Gly Gly Thr Tyr Leu Asp Pro Glu
 210 215 220

Ala Ala Ala Ala Gly Ala Ala Ala Val Ala Asn Gln Gly Asn Lys
 225 230 235

<210> 49

<211> 729

<212> DNA

<213> Corynebacterium glutamicum

<220>

<221> CDS

<222> (101)..(706)

<223> RXA00381

<400> 49

aaacctggtt ttgttcttcc gctctcacgg acgatgattt ctccaagatc gagcaggcac 60

tcaagccgc cgcacgtgca gcagcagaag cgaaggatc atg acg caa acc att 115
 Met Thr Gln Thr Ile
 1 5

gtc cat cta gtt cgc cac ggc gaa gtc cac aac cca gag aaa atc ctg 163
 Val His Leu Val Arg His Gly Glu Val His Asn Pro Glu Lys Ile Leu
 10 15 20

tac gga cgc atg ccc gga tac agg ttg tct tcc cgt gga cgc agc caa 211
 Tyr Gly Arg Met Pro Gly Tyr Arg Leu Ser Ser Arg Gly Arg Ser Gln
 25 30 35

gcc gcc cgc act gca gct tct ttt gaa ggc cac gat gtc acc tac att 259
 Ala Ala Arg Thr Ala Ala Ser Phe Glu Gly His Asp Val Thr Tyr Ile
 40 45 50

gcg gcc tcc cca ttg cag cgt gtg cag gaa acc tcc gaa ccg ttc atc 307
 Ala Ala Ser Pro Leu Gln Arg Val Gln Glu Thr Ser Glu Pro Phe Ile